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Abstract
The decidua and placenta are immune organs, as most of their functions are mediated by immune cells:
implantation, vascular remodeling, and maternal-fetal tolerance. However, how their resident immune
cells accomplish each element and promote the growth of a semi-allogeneic fetus is unknown. Research
in reproductive immunology has largely focused on the role of systemic maternal T cells in maintaining
maternal-fetal tolerance or descriptive studies of the maternal-fetal interface at a single time point in
gestation. Furthermore, how these immune cells may contribute to diseases of pregnancy is less
understood. The goal of this study is to understand the changes that occur over gestation in the immune
populations of the decidua and placenta and how they affect pregnancy outcomes. In humans, these
organs are only available for research at two time points: early in gestation after a spontaneous or
elective abortion, or postpartum after the massive physiologic change of parturition. As such, we utilize
three mouse models of common pregnancy outcomes: (1) parturition, (2) intrauterine fetal demise (IUFD),
and (3) fetal neuronal injury. In each model, extensive flow cytometry was completed to characterize
alterations in immune composition and function both systemically and at the maternal-fetal interface, in
addition to other experimental tools. We find that term parturition involves a loss of immune regulation,
and conversely that preterm parturition recruits inflammatory populations. In a model of IUFD, we utilize
known information about maternal systemic regulatory T cells (Tregs) to rescue this adverse outcome
and then investigate how systemic changes impact the local immune composition using single-cell RNAsequencing. Finally, using a model of fetal brain injury, we identify a plausible mechanism by which
inflammation progresses through tissue compartments at the maternal-fetal interface, ultimately causing
pathologic IFN⯑ production in the fetal brain. Together these findings demonstrate the diverse roles of
the immune populations in the decidua and placenta, and their impact on perinatal outcomes.
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ABSTRACT
IMMUNE MODULATION AT THE MATERNAL-FETAL INTERFACE
REGULATES PERINATAL OUTCOMES
Emma L. Lewis
Michal A. Elovitz
The decidua and placenta are immune organs, as most of their functions are mediated by
immune cells: implantation, vascular remodeling, and maternal-fetal tolerance. However,
how their resident immune cells accomplish each element and promote the growth of a
semi-allogeneic fetus is unknown. Research in reproductive immunology has largely
focused on the role of systemic maternal T cells in maintaining maternal-fetal tolerance
or descriptive studies of the maternal-fetal interface at a single time point in gestation.
Furthermore, how these immune cells may contribute to diseases of pregnancy is less
understood. The goal of this study is to understand the changes that occur over gestation
in the immune populations of the decidua and placenta and how they affect pregnancy
outcomes. In humans, these organs are only available for research at two time points:
early in gestation after a spontaneous or elective abortion, or postpartum after the massive
physiologic change of parturition. As such, we utilize three mouse models of common
pregnancy outcomes: (1) parturition, (2) intrauterine fetal demise (IUFD), and (3) fetal
neuronal injury. In each model, extensive flow cytometry was completed to characterize
alterations in immune composition and function both systemically and at the maternalfetal interface, in addition to other experimental tools. We find that term parturition
involves a loss of immune regulation, and conversely that preterm parturition recruits
inflammatory populations. In a model of IUFD, we utilize known information about
vi

maternal systemic regulatory T cells (Tregs) to rescue this adverse outcome and then
investigate how systemic changes impact the local immune composition using single-cell
RNA-sequencing. Finally, using a model of fetal brain injury, we identify a plausible
mechanism by which inflammation progresses through tissue compartments at the
maternal-fetal interface, ultimately causing pathologic IFNg production in the fetal brain.
Together these findings demonstrate the diverse roles of the immune populations in the
decidua and placenta, and their impact on perinatal outcomes.
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Chapter 1: Introduction
The “maternal-fetal interface” refers to the continuously changing interaction between
maternal and fetal cells at the decidua, the specialized uterine epithelium of pregnancy,
and the placenta. During pregnancy, there is a blurring of the border between maternal
and fetal tissues. Fetal trophoblasts enter the maternal decidua and maternal immune cells
enter the fetal placenta (Semmes et al., 2022) (Figure 1.1). At this interface, both fetal
and maternal cells remodel the uterine vasculature to dilate and extend it to the placenta,
allowing blood flow carrying oxygen and nutrients to the fetus (Ander et al., 2019). The
mouse and human both have hemochorial placentation (Figure 1.1), but the human
placenta is more invasive. In the human placenta, chorionic villi directly bathe in
maternal blood and the syncytiotrophoblasts are a single layer between maternal and fetal
blood (Ander et al., 2019; Semmes et al., 2022). In comparison, the mouse placental villi
form a labyrinth with both cytotrophoblasts and syncytiotrophoblasts between maternal
and fetal blood (Figure 1.1) (Ander et al., 2019). This chapter will begin with an
examination of the historical theories of reproductive immunology and then give an upto-date overview of the immunology of pregnancy from pre-implantation to long
postpartum.
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Figure 1.1: Anatomy of the maternal fetal interface. This illustration zooms in onto the interface
between the maternal myometrium (pink) and decidua (orange) and the fetal placental (purple). All cells
colored purple are of fetal origin. This diagram merges some features of both the mouse and human
placenta. The extravillous trophoblasts (EVTs) are intermediately invasive, while would be more invasive
into the spiral arteries in the human. The trophoblast giant cells along the border between the decidua and
placenta are only present in the mouse placenta, instead layers of EVTs demarcate this border in the human.
The chorionic villi only have one cell layer, which is true in the human placenta, while they would have 2-3
cell layers making up the “labyrinth” in the mouse placenta. Outside of the chorionic villi in the placental
space, where there are both maternal macrophages and fetal hofbauer cells (fetal macrophages) is filled
with maternal blood bathing the chorionic villi and inside of the villi are the fetal vessels. Figure created
using BioRender.

Medawar’s Mistakes
Peter Medawar famously described the “immunological problem of pregnancy” and
called viviparity “teleologically inept” (Medawar, 1953). Medawar postulated three
criteria of mammalian pregnancy that would explain what is now known as “Medawar’s
2

Paradox”: (1) Anatomic separation between mother and fetus, (2) fetal “antigenic
immaturity”, and (3) maternal “immunological inertness” (Male, 2020; Medawar, 1953).
Medawar’s hypotheses led to the growth of the field of reproductive immunology, and his
hypotheses have been the inspiration for generations of experiments. However,
Medawar’s initial three tenants of mammalian reproduction have mostly been refuted.
Pregnancy is a specialized maternal immune state – not one of “paradox” or “inertness”
– but an intricately organized bidirectional interaction between maternal and fetal cells.
The concept of anatomic separation, or that the placenta is a barrier, remains relevant in
that that placenta does protect the fetus and filter out some incoming particles. However,
there is intermixing of maternal and fetal cells on both a local and systemic level.
Locally, fetal extravillous trophoblasts (EVTs) invade maternal spiral arteries, replacing
maternal endothelial cells with fetal trophoblast-derived endothelium (Ander et al.,
2019). Maternal immune cells also make up the majority of CD45+ cells in the
developing placenta, a fetal organ (Lewis et al., 2018). Systemically, levels of fetal
microchimeric cells increase in the maternal blood stream during pregnancy, reaching
approximately 100 fetal cells per milliliter of maternal blood by term (Kinder et al.,
2017). Clearly, the separation between maternal and fetal cells is less solid than once
thought.
The second and third assumptions have to do with the status of maternal and fetal
immune cells. At the human maternal fetal interface, fetal cells, such as EVTs, express
human leukocyte antigen (HLA) molecules, specifically HLA-C, HLA-E, and HLA-G
(Vento-Tormo et al., 2018). These are mature antigens that interact with maternal
decidual natural killer cells (NK cells), which express killer immunoglobulin-like
3

receptors (KIRs) that directly bind HLA molecules on EVTs (Hiby et al., 2004; VentoTormo et al., 2018; L. Xu et al., 2021). In maternal systemic immunity, B cells make
lasting alloantibodies to fetal antigens in ~50% of women after their first pregnancy,
increasing with subsequent pregnancies, and maternal CD4+ and CD8+ T cells have
immunologic memory to fetal antigens (Kinder et al., 2020; Porrett, 2018; Suah et al.,
2021). These interactions refute both the “antigenic immaturity” of fetal cells and
“immunological inertness” of maternal cells (Medawar, 1953). Maternal and fetal cells
do function differently during pregnancy than in Medawar’s points of comparison:
transplantation and infection. He recognized that immune cells had a distinct phenotype
during pregnancy, but incorrectly assumed that they were not antigenic or active.
Instead of viviparity as “teleological inept” (Medawar, 1953), pregnancy is a state of
immunologic complexity, which can teach us about other immune states that intricately
balance inflammation and tolerance, such as the immune response to malignant tumors,
wound healing, and bone marrow transplant. The pregnant body undergoes massive
systemic changes and challenges: in cardiac output, in hormonal milieu, and in immune
composition. The following chapter will first outline what we know so far about the
immune complexity of pregnancy, both locally at the maternal-fetal interface and
systemically in maternal circulation and lymphatic system.
Mucosal Immunity of the Maternal Fetal Interface
The decidua, the specialized uterine epithelium that develops during pregnancy, is an
incredibly complex tissue: it has highly developed endocrine and immune functions; it
starts as a secretory mucosal epithelium, becomes an active interface that creates the
vasculature between two semi-allogeneic organs, and then undergoes regulated cell death
4

to be shed from the body. While there have been many studies of tissue-resident and
mucosal immune cells in the gastrointestinal tract, lungs, and skin, the immune milieu of
the female reproductive tract, particularly during pregnancy has been underexplored. The
following segments will describe how decidual immune populations change in both
composition and function chronologically through each stage of pregnancy.
Uterine Receptivity
The epithelial lining of the nonpregnant uterus, the endometrium, is made up of
columnar epithelial cells with short microvilli (Corbeil et al., 1985). The endometrium is
a highly unique epithelium because it cycles – with a complete cycle occurring in 28 days
in the human or 4 days in the mouse. This cycling is determined by timed fluctuations in
sex steroid hormones and fundamentally alters the tissue structure of the endometrium
(Verma, 1983). During each cycle in mice and humans, the epithelial cells proliferate,
mature, secrete mucus, and then degenerate. In humans, the degeneration involves the
sloughing off of dead epithelial cells during menses, and apoptosis or autophagy of other
epithelial and secretory cells (Verma, 1983). In mice, at the estrus-to-metestrus transition,
the uterine epithelium is disorganized and disrupted with blebbing apoptotic cells and
autophagy (Corbeil et al., 1985). In both mice and humans, it is the mucus-producing
stage (estrus in mice and secretory phase in humans) at which the uterus is receptive for
the implantation of fertilized eggs. This uterine mucosal cycling continues throughout the
female reproductive years.
Uterine reproductive cycling includes specific immunologic changes in addition to the
hormonal and anatomic, and these immune changes play critical roles in whether the
uterus is “receptive” to blastocyst implantation. In estrus, the murine receptive period,
5

regulatory T cells (Tregs) and mast cells are increased in the uterus (Figure 1.2) (Teles et
al., 2013; Woidacki et al., 2015). Uterine mast cells are thought to provide the proteases
necessary to break down the uterine epithelial layer and allow for implantation (Woidacki
et al., 2015). Tregs are thought to minimize the inflammation and scarring of
implantation (Teles et al., 2013). When Tregs are depleted prior to mating, few to no
embryos implant – in both allogeneic and syngeneic pregnancies – and the uterus has
become fibrotic (Teles et al., 2013). Trophoblast invasion and mast cell protease
production create a wound in the uterus, and without Tregs this wound becomes fibrotic
and causes uterine-based infertility.

Figure 1.2: Uterine receptivity promotes blastocyst implantation. This figure demonstrates the key
immune cells in the uterus in estrus that contribute to the ability of a blastocyst to implant. The blastocyst is
an early stage of the developing embryo, prior to its implantation into the uterus and connection to maternal
blood. The trophectoderm will become the chorionic membrane and placenta; the primitive endoderm will
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become the amniotic membrane; and the epiblast will become the body of the embryo. Figure created using
BioRender.

The endocrine and immune systems do not work independently; rather immune cells
often have hormone receptors and respond to environmental hormonal changes. In
transwell in vitro studies, Tregs migrate in response to human chorionic gonadotropin
(hCG), which has been suggested as a way that Tregs increase in the uterus following
fertilization (Schumacher et al., 2009). Tregs are also increased in uterine-draining lymph
nodes (uLN) shortly after copulation due to signals from seminal fluid (Teles et al.,
2013). Studies comparing the uLNs of dams mated to normal males versus males without
seminal vesicles have shown that seminal fluid increases Tregs in murine uLNs by the
time of vaginal plugging (Teles et al., 2013). Together these demonstrate that a variety of
signals and cell types are necessary to create a uterus receptive to an implanting
blastocyst.
Implantation and Placentation
While Tregs are critical to creating a receptive uterine environment, decidual NK cells
have been the primary focus of studies on the immune populations of the maternal-fetal
interface once the blastocyst attaches. In the first trimester, NK cells make up 70% of
decidual leukocytes with 25% macrophages and 5% T cells (Mor et al., 2017). Decidual
NK cells are a distinct subset from peripheral NK cells, with a CD56bright CD16phenotype (Erlebacher, 2013; Hanna et al., 2006; Koopman et al., 2003). NK cells are
thought to guide implantation through direct contact with trophoblasts from the blastocyst
(Hanna et al., 2006). Three types of decidual NK cells have been identified: dNK1,
dNK2, and dNK3. dNK1 cells are the primary subset and they express a large variety of
7

KIRs, which bind to major histocompatibility complex class I (MHC-I) molecules on
trophoblasts (the MHC-I molecules expressed by human trophoblasts are HLA-C, HLAE, and HLA-G) (Vento-Tormo et al., 2018). Both KIR genes and MHC-I genes have
extensive polymorphism so maternal and paternal genotypes are likely different (Hiby et
al., 2004). Some evidence suggests that the maternal KIR genes and fetal MHC-I genes
must favorably interact for successful pregnancy and that specific KIR – HLA genotype
combinations are at higher risk for obstetric complications. For example, a pregnancy
with the maternal KIR AA genotype and the fetal HLA-C2 gene has an elevated risk of
preeclampsia. The hypothesis is that HLA-C2 and KIR AA do not bind strongly and so
the decidual NK cell is more likely to have an inhibitory reaction to the trophoblasts,
ultimately causing shallow implantation and preeclampsia (Hiby et al., 2004). This is just
one example of a potential molecular mechanism of an obstetric disease based entirely on
trophoblast and maternal immune cell interactions at the maternal-fetal interface.
dNK2 cells express NKG2A/C and E which are receptors that can bind the MHC-I
molecules HLA-E and HLA-G on trophoblasts. dNK3 cells express CCL5, a chemokine
that may help direct EVTs, which express the receptor CCR1 (Vento-Tormo et al., 2018).
Decidual NK cells also express vascular endothelial growth factor (VEGF) and placental
growth factor (PLGF), which are necessary for vascular remodeling (Hanna et al., 2006).
NK cells reach their peak numbers by E8-E10 in mice and then start to decrease from the
decidua, as macrophages become a greater proportion of decidual leukocytes (Cappelletti
et al., 2020).
Macrophages at the maternal-fetal interface (and in other tissues) have been frequently
classified as M1 or M2. Much of the literature on uterine macrophages focuses on the
8

benefits of “M2” macrophages during pregnancy, as an anti-inflammatory, protolerogenic cell type (Meng et al., 2017; X.-Q. Wang et al., 2018; Y.-H. Zhang et al.,
2017). However, the M1/M2 classification oversimplifies the multifactorial roles and
subtypes of macrophages at the maternal-fetal interface. Some authors have suggested
that macrophage polarization shifts between M1 and M2 during pregnancy, with most of
the second trimester the macrophages acting in a dual “M1/M2 profile… displaying both
the pro- and anti-inflammatory phenotype” (Y.-H. Zhang et al., 2017). In other words, the
uterine macrophages do not neatly fit into either category.
In a study of human decidual macrophages from elective terminations, expression of
CD11c was used to segregate the macrophages by fluorescence activated cell sorting
(FACS). Using this method, two different transcriptional profiles by microarray were
identified for the CD11chigh and CD11clow macrophages (Houser et al., 2011).
Interestingly, neither transcriptional profile was consistent with the known transcriptional
signatures of M1 or M2 macrophages. Instead, CD11chigh macrophages expressed lipidassociated genes and were filled with neutral lipid droplets, while the CD11clow
macrophages expressed phagolysosome-associated genes and had high phagocytic
activity (Houser et al., 2011); thus creating two alternative decidual macrophage
subtypes.
With the lack of clarity regarding decidual macrophage phenotypes, other studies have
categorized decidual macrophages by function (Liao et al., 2021; Tagliani et al., 2011;
Yao et al., 2019). These macrophages fall into three different functional categories: (1)
inducing maternal-fetal tolerance; (2) promoting spiral artery remodeling and
angiogenesis; and (3) phagocytosing apoptotic trophoblasts. Tolerance induction by
9

decidual macrophages has been described as driven by the receptor activator of NF-kB
(RANK) and indoleamine 2,3-dioxygenase (IDO) (Gustafsson et al., 2008; Liao et al.,
2021; Meng et al., 2017; Riella et al., 2013; Vacca et al., 2010). RANK on macrophages
directly binds to RANK ligand (RANKL) on trophoblasts and decidual stromal cells.
This binding induces a shift in the macrophages to an anti-inflammatory transcriptional
profile (Meng et al., 2017). Because trophoblasts express RANKL, they induce tolerance
in the macrophages that they encounter. Macrophage depletion leads to fetal loss that can
be rescued by the adoptive transfer of RANK+ macrophages but not by the transfer of
RANK- macrophages – further supporting the role of RANK+ macrophages in maternalfetal tolerance (Meng et al., 2017). The expression of IDO by decidual macrophages
prevents effector T cell activation and promotes Treg induction through tryptophan
catabolism and the catabolite kynurenine (Vacca et al., 2010). Decidual macrophages
may also facilitate tolerance by preventing NK cells from lysing trophoblasts through the
production of IDO and transforming growth factor b (TGFb) as shown through in vitro
co-culture experiments (X.-Q. Wang et al., 2018). These are three specific mechanisms
by which decidual macrophages induce tolerance to trophoblasts at the maternal-fetal
interface.
The second function of decidual macrophages, promoting angiogenesis and spiral
artery remodeling, has not been mechanistically characterized. However, in histologic
examination of human and murine decidua, macrophages line the spiral arteries (Smith et
al., 2009). Much like decidual NK cells, decidual macrophages are also known to
produce VEGF and PLGF, supporting angiogenesis (Yao et al., 2019). Hofbauer
macrophages, fetal primitive macrophages in the placenta, also express VEGF and
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fibroblast growth factor 2 (FGF-2), additional growth factors that support placentation
(Thomas et al., 2020). No mechanistic study has demonstrated how these three cell types
may act to promote vascular remodeling outside of their production of pro-angiogenic
growth factors.
Macrophage efferocytosis is the third key function of decidual macrophages. Maternal
macrophages may indirectly support spiral artery remodeling by phagocytosing apoptotic
cells to maintain an immunologically quiescent environment (Yao et al., 2019). During
trophoblast invasion there is continuous apoptosis of both fetal and maternal cells and
macrophage removal of these apoptotic bodies may prevent the exposure of danger
signals and fetal antigens to other decidual immune cells (Abrahams et al., 2004). This
theory is supported by in vitro studies demonstrating the ability of macrophages to engulf
trophoblasts and electron microscopy images of this occurring in the decidua.
Phagocytosis of trophoblasts in vitro leads to changes in macrophage phenotype
including increased expression of T cell inhibitory molecule, programmed death ligand 1
(PD-L1), and anti-inflammatory cytokine IL-10 (Abrahams et al., 2004; Yao et al., 2019).
This finding demonstrates how the different roles of decidual macrophages are
interdependent, such that phagocytosis of trophoblasts induces a pro-tolerogenic
macrophage phenotype. However, the precise signaling pathways that govern this
interaction remain unknown.
In summary, the processes by which decidual NK cells and macrophages promote
healthy pregnancy can be grouped into two main functions: (1) tolerogenic interactions
with fetal trophoblasts and (2) support of placentation/angiogenesis. Of these two
functions, more mechanistic data exist on how NK cells and macrophages interact with
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trophoblasts – including specific receptor and ligand engagement and their downstream
pathways. However, their support of angiogenesis is less well characterized and mostly
surmised by the spiral artery dysfunction that occurs in the absence of either of these cell
types (Barber & Pollard, 2003; Pollard et al., 1991). Similarly, the role of Tregs in
pregnancy also can fall under these two key functions: tolerance and angiogenesis. Treg
promotion of tolerance to fetal antigen has been studied in numerous mouse models using
traceable fetal antigen (Erlebacher et al., 2007; Kinder et al., 2015; Kinder et al., 2020;
Rowe et al., 2011; Suah et al., 2021). However, Treg depletion in pregnancy leads to
lumen thickening of spiral arteries and disorganized placental vasculature (Care et al.,
2018; Woidacki et al., 2013), indicating that Tregs also affect vascular processes in
pregnancy. The role of Tregs in placentation and vascular remodeling remains an
understudied area.
Parturition
The process of parturition is an intricate sequence of hormonal, muscular, vascular, and
immunologic changes. However, what initiates this process and what controls the timing
of the event are poorly understood. Single-cell RNA-sequencing (scRNAseq) has
characterized the transcriptional changes of placental cells from term deliveries with
(TIL) and without labor (TNL). Maternal macrophages were the cell type with the most
differentially expressed genes (DEGs) between TIL and TNL tissues, with specifically
NFKB1 genes highly upregulated in placentas from the in-labor group (Pique-Regi et al.,
2019), suggesting that macrophages may have an important role in the induction of labor.
While the roles of some immune cells appear critical to the process of normal term
parturition, their roles in preterm parturition (i.e. spontaneous preterm birth) are just
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beginning to be revealed. Preterm parturition, defined as spontaneous birth occurring
prior to 37 weeks gestational age, is associated with significant neonatal morbidity and is
the number one cause of neonatal death in the United States (Liu et al., 2015). In an effort
to decipher the role of immune cells in the timing of parturition, studies have been
performed on the decidua, cervix, and placenta in the context of term and preterm labor.
Decidua from human patients with spontaneous preterm labor (<37 weeks gestation) had
elevated numbers of CD4+ and CD8+ effector memory T cells when compared to
decidua from term pregnancies. These T cells from premature decidua were expressing
granzyme B and perforin – indicating fully activated effector T cell phenotypes (ArenasHernandez et al., 2019). Demonstrating support for this observational finding in humans,
pregnant mice injected intraperitoneally with activating anti-CD3e antibodies at E16.5
undergo preterm labor and demonstrate similar decidual T cell activation. However,
systemic anti-CD3e antibodies also lead to maternal systemic inflammation,
hypothermia, and bradycardia, so whether preterm parturition is induced specifically by
decidual T cell activation or maternal systemic illness in this model is unclear (ArenasHernandez et al., 2019).
Our laboratory has developed a model of intrauterine inflammation (IUI) induced
preterm parturition, in which lipopolysaccharide (LPS) is injected directly into the uterus
(Elovitz et al., 2003). This localized method of inducing preterm parturition does not
cause maternal systemic inflammation, and therefore better represents human preterm
parturition, in which maternal systemic illness is rare (Cappelletti et al., 2020). In this
model, we find neutrophil infiltrates (Figure 2.5) to the decidua and high production of
pro-inflammatory cytokines as the primary immunologic changes prior to preterm birth
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(Tulina et al., 2018). A neutrophil influx generally implies an innate response, while
others have reported effector T cells at the maternal-fetal interface, suggesting an
adaptive response. These two findings are not mutually exclusive – there are likely
multiple etiologies of preterm parturition, which may involve different immune the
mechanisms. The question of what dictates the timing of term labor is still unanswered.
Maternal Systemic Immunity
A parous individual’s systemic immune system is fundamentally altered by pregnancy.
This concept has been long understood anecdotally by women who develop autoimmune
disease postpartum, but more recently has been scientifically studied. The immune state
is altered during pregnancy and does not return to nulligravid immunity postpartum, but
rather becomes an entirely new immunologic baseline. This has been most clearly
established with maternal regulatory T cells (Tregs).
Regulatory T cells
Maternal Tregs expand during pregnancy, with increases of both fetal-antigen specific
Tregs and splenic Tregs as a whole (Rowe et al., 2011; Samstein et al., 2012). The
expansion of Tregs during pregnancy is an evolutionary change that began with the first
placental mammals. Placental mammals mark a critical change in the evolution of
pregnancy: that the fetus and placenta reside inside the mother for the duration of
pregnancy. The evolutionary milestone of placentation coincides with the appearance of
CNS1 in the genome, the transcriptional enhancer necessary for peripheral regulatory T
cell (pTreg) induction (Samstein et al., 2012). While CNS1 is conserved amongst all
placental mammals, marsupials and other non-placental mammals show no evidence of
the conserved CNS1 sequence or a homolog (Samstein et al., 2012). Successful
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pregnancy in placental mammals therefore requires the ability of a Treg to be induced
outside of the thymus, and without pTregs or CNS1, pregnant animals undergo partial
fetal loss (Samstein et al., 2012). Tregs developed in pregnancy do not decrease
postpartum but remain as long-lasting memory Tregs (Rowe et al., 2012).
Studies of Tregs in pregnancy then examined the antigen specificity of pregnancyinduced Tregs. Total Treg depletion leads to significant fetal loss, except in the case of
syngeneic pregnancies with inbred mice or if Treg depletion is initiated after E10.5
(Aluvihare et al., 2004; Shima et al., 2010). These findings led to the hypothesis that
Tregs must specifically be induced against fetal alloantigens early in pregnancy, because
syngeneic pregnancies were mostly unaffected by Treg depletion (Aluvihare et al., 2004).
The initial studies with postpartum mice looked at the CD4+ T cell responses to H-Y
peptide from the Y-chromosome. CD4+ T cells from postpartum parous female mice
responded to H-Y peptide with more proliferation than CD4+ T cells from virgin females
(Kahn & Baltimore, 2010). When Tregs were depleted from the parous CD4+ T cells, the
remaining CD4+ T cells proliferated 3-fold more when exposed to H-Y (Kahn &
Baltimore, 2010). These data demonstrate that at least two cell types, Tregs and effector
CD4+ T cells, are changed during pregnancy and remain changed postpartum.
The finding of postpartum CD4+ T cell changes has been reproduced in multiple
systems of allogeneic pregnancy: Tregs expand in response to fetal antigen and this
expansion is maintained postpartum and augmented in subsequent pregnancies (Kahn &
Baltimore, 2010; Rowe et al., 2012). Because these fetal-antigen Tregs further increase in
subsequent pregnancies, the postpartum maintenance of these Tregs is thought to improve
reproductive fitness. As such, parous people have a fundamentally different CD4+ T cell
15

repertoire than they did prior to pregnancy. The clinical significance of these pregnancyassociated T cells outside of pregnancy and whether they persist after menopause has not
yet been explored.
CD8+ T cells
Pregnancy not only changes the maternal CD4+ T cells repertoire, but also modulates
fetal-specific CD8+ T cells. During pregnancy fetal-specific CD8+ T cells are in a muted
state – not anergic, not classically exhausted, but also not functioning as fully active
antigen-experienced CD8+ T cells (Barton et al., 2017). Much like Tregs, fetal-specific
CD8+ T cells expand during pregnancy and are maintained postpartum. These fetalspecific CD8+ T cells are able to rapidly lyse cells with fetal antigen (i.e. in mouse
models with OVA) when introduced outside of the context of pregnancy (Kinder et al.,
2020). Conversely, in a second pregnancy, fetal-specific CD8+ T cells make less
cytokine and express more exhaustion-associated markers (PD-1, LAG-3, CTLA-4, TIM3) than during a first pregnancy (Kinder et al., 2020). Therefore, the immunologic context
of pregnancy affects the functional state and response to antigen of these CD8+ T cells.
The creation of a permanently altered T cell repertoire due to pregnancy and fetalspecific memory cells has effects for a woman’s lifespan. For example, transplantation is
a clinical scenario where the persistence of pregnancy-associated T cells may alter
outcomes many years postpartum, especially if the transplanted organ comes from the
patient’s offspring. In transplantation, the primary adverse outcome is tissue rejection –
thought to be driven by either alloreactive B cells or CD8+ T cells. In the context of
transplantation, parous mice exposed to OVA-expressing fetuses during pregnancy
rejected OVA heart transplants faster than virgin mice (Suah et al., 2021). Even when
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parous mice were treated with an anti-rejection regimen, they ultimately rejected the
transplant, while the virgin mice did not reject the transplant while on the anti-rejection
regimen (Suah et al., 2021). These data indicate that parity might predispose women to
transplant rejection if the transplanted tissues are from offspring.
However, transplant rejection in this context may be B cell mediated as parous µMT -/mice, which are B cell deficient, respond similarly to virgin females to transplantation,
with full transplant acceptance while on an anti-rejection regimen (Suah et al., 2021).
Donor-specific antibodies are known to facilitate transplant rejection, and pregnancy can
induce anti-fetal antibodies, which would preclude the donor from being the recipient’s
offspring (Porrett, 2018). Anti-fetal antibody production, which indicate the presence of
memory plasma cells, are another example of a long-lasting immune change induced by
pregnancy, with the potential for real clinical consequences later in life.
Microchimerism
Perhaps the most intriguing immune cell change postpartum is microchimerism.
Microchimerism is the bidirectional exchange of cells across the placenta – with fetal
cells residing in maternal tissues and maternal cells in fetal tissues. Microchimerism
peaks during late pregnancy, with an estimated 100 fetal cells/ml of maternal blood
(Kinder et al., 2017). This increase in fetal cells during pregnancy may be responsible for
the continuous increase in maternal Tregs during pregnancy – expanding in response to
an increasing dose of fetal antigen. While not all fetal cells remain in maternal circulation
long-term, cells with offspring DNA have been found during autopsies in the lung,
kidneys, thyroid, liver, and many other organs of parous women (Kinder et al., 2017).
Because these fetal microchimeric cells are long-lived they may also be responsible for
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the persistence of anti-fetal T cells and B cells postpartum. These microchimeric cells are
thought to support tolerance to future pregnancies with the same father, but whether
subsequent pregnancies augment or diminish microchimerism is unclear, particularly if
the subsequent pregnancies have different paternity (Kinder et al., 2015). Unrelated to
reproduction, microchimerism is one theoretical cause of postpartum autoimmunity –
with maternal immune cells reacting to fetal antigens in the thyroid or skin, leading to
autoimmune thyroiditis or systemic sclerosis (Adams & Nelson, 2004). This again
illustrates the potential long-term immunologic consequences of pregnancy.
Immune Modulation at the Maternal Fetal Interface Regulates Perinatal Outcomes
In summary, our knowledge of the immunobiology of pregnancy has progressed greatly
in the last decade. Immune cells in the decidua are clearly critical for uterine receptivity,
implantation, placenta development, and uterine vascular remodeling. Research on
maternal systemic immune populations has greatly focused on T cells and the long-term
changes to T cells that recognize fetal antigen. There is a complex relationship between
maternal and fetal cells that persists beyond pregnancy in the context of microchimerism.
Despite the knowledge gained from many important studies, very fundamental
knowledge gaps still exist.
•

What regulates of the timing of parturition – both term and preterm?

•

How does the immune composition at the maternal-fetal interface change over
gestation? (Most studies report a single gestational timepoint.)

•

How are immune cells mechanistically implicated in pre-implantation failure and
infertility, given that they play a role in uterine receptivity?
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•

What leads to a post-implantation fetal loss? What is the mechanism by which a
fully implanted and growing fetus is rejected?

•

How are macrophages and NK cells that are necessary for spiral artery
remodeling involved in the pathogenesis of preeclampsia? Is preeclampsia an
immune-based disorder?

•

Are maternal systemic immune changes responsible for maternal pregnancy
health? Do they impact gestational diabetes, anti-phospholipid syndrome, and
other maternal systemic diseases in pregnancy?

•

How do immune cells at the maternal fetal interface traffic between anatomic
spaces and tissues?

•

How does a change in the immune composition of the uterus affect fetal
development?

This study utilizes translational mouse models to investigate some of these knowledge
gaps and to specifically examine how local immune changes impact perinatal outcomes.
We investigate three models to respond to three key questions in reproductive
immunology:
(1) How does the placental immune composition shift over gestation and as pregnancy
approaches parturition? In this model we use CD-1 outbred mice to investigate
placental immune shifts that may elicit parturition in healthy pregnancy and in a
model of preterm parturition. We also use congenic CD45.1/CD45.2 C57BL/6 mice
to determine the frequency of maternal versus fetal immune cells in the placenta.
(2) What is the role of maternal Tregs in shaping the uterine resident immune
populations, particularly in mid-gestation? How might these Treg-induced uterine19

resident cells elucidate a mechanism of late fetal loss or intrauterine fetal demise
(IUFD)? In this model we utilize the CBA strain of mice, which have mid-late
gestation fetal loss and rescue their fetal loss phenotype with an adoptive Treg
transfer. We then investigate how this Treg transfer alters uterine myeloid cells
using single-cell RNA-sequencing.
(3) How does asymptomatic intrauterine inflammation cause long-term neuronal
damage to exposed fetuses? How does an inflammatory response traffic through
multiple anatomic spaces? In this model we use a low dose intrauterine injection of
LPS, which we have previously shown to cause fetal brain injury without preterm
birth and examine immune compositional and functional changes over 72 hours
following injection.
These three projects all are based on the same core hypothesis, that the immune
composition at the maternal fetal interface regulates pregnancy outcomes, whether that
outcome is the timing of parturition, late fetal loss, or fetal neuronal injury.
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Chapter 2: Placental immune state shifts with gestational age
Of note, exact text in Chapter 2 and figures 2.1-2.4 and 2.6 have been published in the
following article: Lewis, E. L., Sierra, L.-J., Barila, G. O., Brown, A. G., Porrett, P. M.,
& Elovitz, M. A. (2018). Placental Immune State Shifts with Gestational Age. American
Journal of Reproductive Immunology, 79(6), e12848. https://doi.org/10.1111/aji.12848.
Introduction
The placenta functions as an immunologic organ as evidenced by its ability to defend
the fetus from infection (Bayer et al., 2015; Johnson & Chakraborty, 2012), allow
maternal immune tolerance (Samstein et al., 2012; Svensson-Arvelund et al., 2015;
Tilburgs et al., 2015), and generate immune cells through hematopoiesis (Robin et al.,
2009; Sasaki et al., 2010). While these functions are critical parts of reproductive success,
the immunologic composition of the placenta remains largely unknown. Placental
immunologic functions are both necessary for the maintenance of a healthy pregnancy
and implicated in obstetric complications from pre-eclampsia to chorioamnionitis (Amara
et al., 2013; Benzon et al., 2015; Cotechini et al., 2014; C. J. Kim et al., 2015; Moffett &
Loke, 2006). Further investigation is warranted to elucidate the mechanisms by which the
placenta acts as an immune organ.
Mammalian pregnancy requires the maternal immune system to become tolerant to a
semi-allogeneic fetus while maintaining defense against infection. These conflicting
immunologic roles are of heightened importance in the placenta, where maternal and
fetal-derived cells directly interact, and the fetus requires protection from maternal
21

transmission of infection (Moffett & Loke, 2006). Current research on placental
immunity in these two roles has focused on cytokines. Placental immunosuppressive
cytokines aid in maternal tolerance induction (Mao et al., 2013; Ramhorst et al., 2012;
Roth et al., 1996) and interferon production impacts the response to placental infections
(Bayer et al., 2016; Tabata et al., 2016). Many of these cytokines are produced directly by
trophoblasts, but traditional immune cells also contribute to placental immune functions.
For example, placental fetal macrophages, or Hofbauer cells, aid in prevention of
transplacental passage of HIV infection (Johnson & Chakraborty, 2012). An immune cell
census of the placenta at mid-gestation demonstrated high levels of maternal myeloid
cells (Habbeddine et al., 2014), but the trafficking and function of these placental cells
have yet to be investigated.
The population dynamics of immune cells at the maternal-fetal interface are
particularly important late in gestation, in the context of term or preterm parturition.
Multiple studies have demonstrated an influx of myeloid cells to the decidua,
myometrium, and cervix near term gestation (Gomez-Lopez et al., 2014; Sakamoto et al.,
2005; Shynlova et al., 2013; Young et al., 2002). This cellular infiltrate occurs prior to
the initiation of both term and preterm parturition (Fainaru et al., 2014; Hamilton et al.,
2012), suggesting a role for immune cells in the process of parturition. Despite the
potential involvement of placental immune cells in this process, shifts in the composition
of placental immune populations late in gestation near parturition remain unexplored.
Clinical observations support a role for placental immune cells in parturition.
Examination of postpartum placental histology from term deliveries demonstrates more
frequent placental neutrophil infiltrate amongst women who delivered spontaneously than
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women who were induced (H. S. Park et al., 2010). Placental neutrophil infiltrate also
negatively correlates with gestational length, suggesting a role for placental immune cells
in both healthy and preterm parturition (C. J. Kim et al., 2015). Human studies are limited
by evaluation of a placenta after delivery has occurred. Hence, it cannot be determined
whether the immunologic findings in the placenta precede or are the result of parturition.
Data on placental immune cells, particularly near parturition, are sparse. An
understanding of the role of placental leukocytes requires first the knowledge of what
immune cells populate the placenta and how they change over gestation. We hypothesize
that placental immune cells will shift from an immunoregulatory to an inflammatory state
near term. This change in the immune state could be mediated through either an alteration
of the placental immune census or through functional change of existing immune cells.
To study the population dynamics of placental leukocytes in healthy pregnancy, a daily
placental immune census was conducted from mid to late gestation, detailing changes
both in placental immune populations and cytokine production.
Results
In mid-gestation, placental immune populations are distinct from maternal systemic
immune populations.
Frequencies of multiple innate and adaptive immune cell subtypes were compared
between spleen, blood, and placental tissue by flow cytometry. Granulocytes represented
the majority of the immune cells found in the placenta (Figure 2.1A, G), while B cells
were the primary population in both maternal blood and spleen (Figure 2.1D, G). For
every immune cell type analyzed, the cell frequency in the placenta differed significantly
from that in the maternal blood and spleen (Figures 2.1A-F). At E15, innate cell types
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made up the majority of placental leukocytes (mean = 79.7%) in contrast to maternal
systemic immune tissues, which were dominated by adaptive cells (78.6% and 60.7% in
spleen and blood, respectively) (Figure 2.1G).

Figure 2.1: Placental immune cell distribution differs from that of the maternal spleen or blood.
Placenta, blood, and spleen were harvested from timed-pregnant mice at E15. Immune cells were identified
by flow cytometry. (A-F) Flow cytometry results, quantified as percent of total CD45-positive, live
leukocytes. Differences in immune cell frequency by tissue were determined by one-way-ANOVA with
post-hoc Dunnet’s (A,B,D,F) or Holm-Sidak’s (C,E) multiple comparison test. N=6-12 combined from a
minimum of 2 replicate experiments. Error bars show standard error. *:p<0.05, **:p<0.01, ***:p<0.001,
****:p<0.0001. (G) Mean immune cell frequencies from each tissue presented as pie charts.
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Placental immune cells are mostly maternal in origin.
Because the placental immune populations differed so significantly from systemic
immune populations, the origin, maternal or fetal, of placental immune cells was
investigated. Congenic CD45.1 sires were mated to wild-type C57BL/6 CD45.2 dams to
differentiate between maternal and fetal CD45-positive leukocytes. In these experiments,
maternal leukocytes exclusively express CD45.2, while fetal leukocytes express both
CD45.1 and CD45.2 (Figure 2.2A). There is a clear predominance of maternal immune
cells in the placenta (mean = 95.7±0.6%) (Figure 2.2A). Fetal immune cells represent a
unique population of placental immune cells, with a significantly different distribution
than maternal immune cells in the placenta (Figure 2.2B). Fetal-derived cells in the
placenta are mostly F4/80-positive macrophages, with some granulocytes and minimal
adaptive immune cells. In contrast, the maternal immune cells in the placenta include
high frequencies of both B cells and granulocytes (Figure 2.2C).
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Figure 2.2: Placental immune cells are primarily maternal in origin. Congenic CD45.1 sires were
mated with wild-type C57BL/6J female mice, expressing CD45.2. At E18-E19, placenta, maternal spleen,
and fetal liver were collected and tissue immune cells were quantified by flow cytometry. (A) Maternal
spleen and fetal liver were used to set gates to differentiate maternal from fetal cells. (B) Frequency of
immune cell types was quantified as a percentage of the total maternal (CD45.2-positive cells) or fetal
(CD45.1 and CD45.2 double positive cells) placental leukocytes. Fetal versus maternal cell frequencies
from the same pregnancy were compared by paired t-test. Error bars show standard error. *:p<0.05,
**:p<0.01, ***:p<0.001, ****:p<0.0001. (C) Mean maternal and fetal immune cell frequencies presented
as pie charts.

Placental immune cell census changes as pregnancy approaches term.
The placental immune census was measured daily in pregnant CD-1 mice from E15 to
near parturition at E19. (Term pregnancy is 19.5 days.) Granulocytes represent the
majority of placental immune cells on all days examined (Figure 2.3A). The frequency of
many immune cell types was consistent from mid to late gestation, including
granulocytes, macrophages, B cells, and both CD4 and CD8 T cells (Figures 2.3A, B, D,
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E). Notably, both CD11c-positive myeloid cells and CD4-positive, FoxP3-positive
regulatory T cells (T-regulatory or Tregs) decrease in frequency as pregnancy approaches
term (Figures 2.3C, F). These two immune cell types show a significant decrease from
E15 to E19, whether measured as a frequency of placental leukocytes or as absolute
cell number (Figures 2.3G, H).

Figure 2.3: Placental immune populations change as gestation approaches term. Placentae from
timed-pregnant CD-1 mice were harvested daily from E15-E19 and immune cells were quantified by flow
cytometry. (A-F) Specific immune populations quantified daily as the percentage of total placental CD45-
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positive, live leukocytes. (G, top panels) Representative flow plots of CD11c-positive cells, gated on
singlet, live CD45-positive cells. (H, top panels) Representative flow plots of FoxP3-positive T cells, gated
on singlet, live, CD45 and CD4-positive cells. (G-H, bottom panels) Flow cytometry plots quantified as
both frequency of total CD45-positive leukocytes and absolute cell count. Differences between E15 and
E19 were assessed by unpaired t-test with Welch’s correction or Mann-Whitney test, for data with or
without a normal distribution, respectively. Error bars show standard error. **p<0.01. N=12 for E15 and
E19, N=6 for E16, E17, and E18.

Placental levels of IL-35 and IL-9 decrease near term.
To analyze the potential functional significance of this decrease in both CD11c-positive
myeloid cells and Tregs, levels of placental cytokines associated with these cell types
were measured from mid to late gestation. Tregs traditionally produce IL-10, IL-35 and
TGFβ1 as one mechanism to exert their immunosuppressive function (Schmidt et al.,
2012). Cytokines IL-10 and TGFβ1 were unchanged from E15 to E19 (Figures 2.4B, F),
while IL-35 decreased near term (Figure 2.4E). Cytokines associated with Treg loss and
Th17 cells, IL-17 and IL-23, also remained constant (Figures 2.4C, D). IL-9, reported to
be abundant in the murine placenta at mid-gestation (Habbeddine et al., 2014), decreased
from E15 to E19 (Figure 2.4A).
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Figure 2.4: Placental cytokine levels from mid-gestation to term. Cytokines in placental protein
lysate were measured by ELISA and normalized to total placental protein. Placentae were collected at
indicated gestational age. Statistical analysis completed by unpaired t-test or Mann-Whitney test for data
with or without a normal distribution, respectively. Error bars show standard error. ****:p<0.0001. N=7,
combined from two replicate experiments.

Placentae from preterm and term parturition display different immune pathways.
Given that we saw immune changes in the placenta at term, we decided to see if we
found these same changes during preterm parturition. Using our already established
model of intrauterine preterm birth, we compared four groups of mice: (1) untreated E15
mice, (2) untreated E19 mice – prior to E19.5 term parturition, (3) E15 mice 6 hours after
receiving intrauterine saline, (4) E15 mice 6 hours after receiving intrauterine LPS – prior
to preterm parturition. At this dose of intrauterine LPS (250µg), 100% of dams deliver
within 5 to 24 hours, without any morbidity to the dams (Elovitz et al., 2003). Immune
populations in the placenta and decidua of each of these four groups were assessed by
flow cytometry. The E19 term mice had a decrease in placental Tregs compared to E15
mice (Figure 2.5A), replicating our prior results (Figure 2.3H). There were no placental
immune changes detected between the saline and preterm mice. However, there was a
large increase in neutrophils to the decidua in the preterm mice, not present in the term
mice (Figure 2.5D). We then used cytokine ELISAs to determine whether there were
similar placental cytokine signals between term and preterm parturition. Consistent with
our previous data (Figures 2.4A, E), IL-35 and IL-9 decreased in the E19 term parturition
mice, but were unaffected in the preterm mice (Figures 2.5B, C). Alternately, placentae
from the preterm mice had large elevations in IL-6 and CCL5, not seen in the term mice
(Figures 2.5E, F).
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Figure 2.5: Placentae and decidua have different immune responses prior to term versus preterm
parturition. Placentae and decidua were harvested from timed-pregnant mice for (A, D) immune cell
quantification by flow cytometry and (B,C,E,F) cytokine quantification by ELISA. The four groups of
timed pregnant mice included: E15 and E19 untreated mice, and mice sacrificed 6 hours after receiving
intrauterine injections on E15 of either saline (controls) or 250µg LPS, a dose that causes 100% preterm
birth in under 24 hours. (A) Placental regulatory T cells and (D) decidual neutrophil levels differed between
the groups. Placenta cytokines (B) IL-35, (C) IL-9, (E) IL-6 and (F) CCL5 also demonstrated differences
between groups. Statistical analysis was completed by one-way ANOVA with post-hoc Sidak’s multiple
comparison test comparing E15 to E19 mice and saline to preterm mice. **:p<0.01; ***:p<0.001;
****:p<0.0001.

Discussion
This study is the first to characterize placental immune population dynamics near
parturition and to provide a daily placental immune census from mid to late gestation.
Prior studies have examined placental immune cells – both in human postpartum
placentae, or murine placentae at mid-gestation, but not over time near parturition
(Habbeddine et al., 2014; H. S. Park et al., 2010). As these prior studies did not address
what occurs from mid-gestation to parturition, our results address this important gap in
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knowledge. Investigation of the immune census in late gestation demonstrates stable
populations of most subtypes of placental immune cells, distinct from maternal systemic
immune populations, with alterations in regulatory cells and cytokines at term. These
findings may serve as a baseline for placental immunology in healthy pregnancy.
Understanding the normal immunological changes during a healthy pregnancy will now
allow one to query how adverse pregnancy outcomes might perturb or modify these
immunological changes.
A major finding of this study was the decrease in both CD11c-positive myeloid cells
and Tregs in the placenta near term parturition (Figure 2.6). Tregs are necessary for
successful murine pregnancy and are generated in the periphery from CD4-positive T
cells with T cell receptors that recognize fetal antigen (Aluvihare et al., 2004; Kahn &
Baltimore, 2010; Kinder et al., 2015; Rowe et al., 2011, 2012; Samstein et al., 2012;
Shima et al., 2010). However, the mechanism and location of this fetal antigen-specific
Treg induction is unknown. CD11c-positive myeloid cells, specifically tolerogenic
dendritic cells, are able to induce Tregs (Coombes et al., 2007; Sun et al., 2007). The
interaction of these two cell types in the placenta may be involved in establishing and
maintaining fetal-maternal tolerance, suggesting that their decrease represents a loss of
immune regulation near term. Whether loss of immune regulation contributes to
parturition is unknown.
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Figure 2.6: Illustrated model demonstrating key changes in the placenta from mid to late gestation
in healthy pregnancy.

Our cytokine data support the hypothesis that placental immune regulation near term
parturition is diminished. The decrease in IL-35 and IL-9 demonstrate a loss of
suppressive cytokines near term. IL-35 and IL-9 enhance Treg differentiation and
function (Collison et al., 2007; Elyaman et al., 2009). The decrease in these cytokines at
term compared to earlier in pregnancy is consistent with the finding of a decrease in
Tregs. However, we cannot conclude that the change in cytokine levels is directly related
to the loss of Tregs because other cell types, including trophoblasts, make IL-35
(Collison et al., 2007; Roth et al., 1996; Schmidt et al., 2012). IL-35 and IL-9, in
comparison to other regulatory cytokines, are particularly implicated in tolerance to
allografts (Gorczynski et al., 2014; Olson et al., 2013), so may function similarly to
promote maternal tolerance of fetal tissue. Together the decreases in regulatory cells and
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cytokines demonstrate a shift in the cytokine milieu at the maternal-fetal interface near
parturition. Prior studies have described inflammatory infiltrates to the decidua prior to
parturition but have not examined the placenta or shown a loss of immune regulation near
term (Hamilton et al., 2012; Shynlova et al., 2013). This study supports a potential role of
the immune system in parturition, but the initiators and sequence of the labor cascade
remain unclear.
This study also demonstrates that the placenta, while a highly perfused organ from
maternal cardiac output, does not simply reflect maternal blood leukocytes, but harbors
its own maternal immune populations. While future studies are required to understand the
stability, kinetics, and origin of placental leukocytes, the significant difference between
the immune cell census of the placenta and maternal blood suggests a novel placentalresident immune system. This finding has implications for the use of peripheral blood as
a “window” into the maternal-fetal interface. Our data suggest that examination of
maternal peripheral blood will not reflect the immune state of the maternal-fetal interface
during pregnancy. Consequently, our findings suggest that testing the immune profile in
maternal blood will not accurately predict what is occurring at the level of the placenta or
the maternal-fetal interface. The maternal immune cells in the placenta may also have
different roles from the same cell types systemically, as tissue-resident immune
populations are known to have functions specific to the tissue (Burzyn et al., 2013;
Davies et al., 2013). Thus, it is biologically plausible that placental immune cells may
have non-traditional immune functions specific to their placental niche and that these
functions may play a role in normal and abnormal pregnancies.
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The finding of a unique maternal immune census in the placenta requires further
investigation. One limitation of this study is that we did not assay for many known tissueresident lymphocyte populations (e.g. NKT cells, γδ T cells, innate lymphoid cells) (Fan
& Rudensky, 2016). Future studies are necessary to determine if these classic tissueresident lymphocytes populate the placenta.
A unique strength of our model is the use of outbred mice. Using inbred strains of mice
to study human pregnancy can be limited since the mother and fetus are genetically
identical, and thus the fetus is syngeneic to the mother. The allogenicity of the fetus
affects the immune cells and cytokines at the fetal-maternal interface (Habbeddine et al.,
2014). Murine studies have also demonstrated that pregnancy outcomes differ following
an immunologic intervention depending on whether the fetus is syngeneic or semiallogeneic (Aluvihare et al., 2004; Erlebacher et al., 2007; Guleria et al., 2005). Outbred
CD-1 mice are genetically diverse; the genetic composition of the fetus therefore diverges
significantly from the mother and is semi-allogeneic, which more closely mimics human
pregnancy.
While the focus of this study is term parturition, we asked whether the placenta would
demonstrate similar immunologic shifts during preterm parturition. For example, low
numbers of Tregs in humans are associated with preterm birth (Koucký et al., 2014),
consistent with our finding of a decrease in placental Tregs at term. However, we did not
find a decrease in placental Tregs in preterm parturition, nor a loss of regulatory
cytokines. In contrast, we found an increase in placental pro-inflammatory cytokines,
specifically IL-6 and CCL5. This indicates that preterm parturition is not simply early
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term parturition, but involves a separate immune involvement and pathogenesis beyond a
change in timing.
Novel to this work, our findings suggest that IL-9 and IL-35 may be of greater
importance, at least in the setting of term parturition. These cytokine changes were not
present in preterm birth, consistent with existing work that investigates IL-9 in patients
with preterm birth, in which no difference was found (Laudanski et al., 2014). As
immune regulation is believed to be important in the pathogenesis of spontaneous
preterm birth, future studies may look at other regulatory cytokines in the setting of
preterm parturition.
This work, characterizing shifts in the placental immune census in healthy pregnancy,
allows future study of the placenta in the setting of a variety of obstetric complications,
not only preterm birth. These findings begin to explain correlative data on the immune
system’s impact on obstetric disease in human pregnancy. For example, low levels of
both serum IL-35 and serum Tregs are associated with recurrent miscarriage (Kwiatek et
al., 2015; Yue et al., 2015). Low levels of IL-35 have also been correlated with an
increased risk of preeclampsia (Ozkan et al., 2013), while the role of Tregs in
preeclampsia is debated (Paeschke et al., 2005; Toldi et al., 2015). Dendritic cells from
pregnant women with preeclampsia produce more IL-23 than healthy pregnant women,
leading to greater expression of IL-17 and IFNΥ by co-cultured T cells, implying the
differentiation of inflammatory over regulatory T cell subtypes (J. Wang et al., 2014).
Future investigations using this murine model will examine how aberrations in the
immune cells of the placenta – due to infection, maternal genetic factors, or inflammatory
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conditions – could lead to many obstetric pathologies including preeclampsia,
miscarriage, and preterm birth.
Methodology
Mice: Timed-pregnant CD-1 mice were purchased from Charles River Laboratories
(Wilmington, MA). Animals were shipped 8-12 days after mating and allowed to
acclimate in the animal facility for 3-7 days, until indicated gestational age. Outbred CD1 mice mimic the genetic diversity between fetus and mother of human pregnancy.
C57BL/6J female mice and congenic B6.SJL-Ptprca Pepcb/BoyJ male mice were
purchased from The Jackson Laboratory (Bar Harbor, ME) and timed matings were
performed. Female mice were checked daily for vaginal plugs to determine gestational
age. These congenic matings were used to differentiate between maternal and fetal
immune cells. For the preterm birth model, on E15, pregnant mice underwent a minilaparotomy, while under isoflurane anesthesia. Each mouse received an injection into
their right uterine horn, between the first and second amniotic sacs proximal to the cervix,
as previously described (Burd et al., 2009; Elovitz et al., 2003, 2006). Each injection was
either 100µl sterile phosphate buffered saline (saline control group) or 250µg/100µl
lipopolysaccharide (LPS)/sterile PBS (preterm group). LPS was from E. coli 055:B5
(Sigma, St. Louis, MO). Mice were then euthanized by CO2 6 hours post-intrauterine
injection, with tissues collected only from mice that were still pregnant. At this dose of
LPS, 100% of injected dams will give birth within 24 hours (Elovitz et al., 2003). All
experiments were performed in accordance with the National Institute of Health
Guidelines on Laboratory Animals with approval from the University of Pennsylvania’s
Animal Care and Use Committee.
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Tissue Collection: Pregnant mice were sacrificed on embryonic days 15-19 (E15-19)
(n=6 mice/day). In replicate experiments, mice were sacrificed at E15 and E19 (n=6
mice/day). Whole blood was obtained by cardiac puncture, followed by harvest of
placentae and spleen. All placentae were removed from the uterus, stripped of all
membranes, and rinsed with cold HBSS + 10% FBS. Eight placentae from the same dam
were pooled for immediate use in flow cytometry and considered an N=1. Additional
placentae, from dams with greater than eight gestational sacs, were frozen at -80°C for
future protein analysis.
Single Cell Suspension: Pooled placentae (N=8/dam) and spleen were minced and
incubated in digest solution (HBSS with 1mg/ml collagenase IV and 10% FBS) for 30
minutes in a 37°C water bath. Digested organs were then strained through both 70µm and
40µm cell strainers and cells were pelleted by centrifugation. ACK lysis buffer was used
to remove red blood cells from spleen, placentae, and whole blood. Remaining cells were
centrifuged and then passed through 35µm filter caps into FACS tubes.
Flow Cytometry: Cells were stained with Live/Dead Aqua and then incubated with
mouse BD FcBlock (BD Biosciences, San Jose, CA). Cells were incubated with a surface
staining antibody panel for 30 minutes at 4°C. The panels included CD45.1-BV421,
CD45.2-BV785, Ly6G-PerCP.Cy5.5, CD11c-PE.Cy7, CD19-APC, CD4-BV605
(BioLegend, San Diego, CA), pan-CD45-BV711 (BD Biosciences, San Jose, CA), F4/80FITC (Invitrogen, Carlsbad, CA), MHC-II-AF700, and CD8-APC.eF780 (eBioscience,
San Diego, CA). Cells were then fixed and permeabilized, followed by intracellular
staining by FoxP3-PE, according to the eBioscience FoxP3 Transcription Factor Staining
protocol (eBioscience, San Diego, CA). CompBeads (BD Biosciences, San Jose, CA)
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stained with a single antibody were used for compensation. Cells were analyzed using a
BD LSR-II (BD Biosciences, San Jose, CA).
ELISA: Placental cytokines were measured at E15 and E19 (N=7 mice/day). Placental
tissue (50-100mg) was submerged in RIPA buffer (G-Biosciences, St. Louis, MO)
prepared with 1 complete mini protease inhibitor tablet (Roche Diagnostics, Indianapolis,
IN) and homogenized on the TissueLyser II (Qiagen, Germantown, MD) with a 5mm
steel bead at a frequency of 30/s for 10 minutes. Homogenized tissue was incubated on
ice for 30 minutes, centrifuged at 14000rpm, and supernatant was collected and analyzed
by ELISA. Specifically, CCL5, IL-6, IL-10, IL-17, IL-23, and TGF-β1 were measured by
Quantikine ELISA kits (R&D Systems, Minneapolis, MN) and IL-9 and IL-35 were
analyzed by Legend Max ELISA kits (Biolegend, San Diego, CA), following
manufacturers’ protocols. Total isolated protein was measured using a BCA protein assay
kit (Pierce, Rockford, IL) and cytokine levels were normalized to total protein.
Analysis: Flow cytometry data were analyzed by FlowJo. Statistical analyses were
performed using GraphPad Prism. To assess differences between tissues, a 1-way
ANOVA was used followed by Dunnett’s multiple comparisons test when groups were of
similar variance and Holm-Sidak’s multiple comparisons test when groups differed in
variance, as assessed by Brown-Forsythe test. Paired t-tests were used to compare
maternal and fetal cells derived from the same placenta. Two-tailed unpaired t-tests were
used to compare two time points using tissue from different animals at each time point.
Welch’s correction was applied to unpaired t-tests if the two groups differed in variance
by F test. Normality was assessed by Shapiro-Wilk test. When data were not normally
distributed, a Mann-Whitney test was used instead of a t-test.
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Chapter 3: Regulatory T cells increase a novel Trem2+ MHC-IIlow
uterine macrophage population and promote healthy pregnancy
Introduction
Human fetal loss after 20 weeks of gestation is known as an intrauterine fetal demise
(IUFD), commonly referred to as stillbirth. In the United States, IUFD affects 6
pregnancies for every 1,000 live births (Dongarwar et al., 2020). The cause of death in
IUFD is unknown in nearly two-thirds of cases (Man et al., 2016). The remaining onethird are caused by either a maternal complication or fetal congenital abnormality (Man
et al., 2016). Certain features are frequently present in cases of IUFD of unknown
etiology – abnormal placentation, intrauterine growth restriction, histological
chorioamnionitis, and elevated maternal white blood cell counts (Harrison et al., 2018).
Placental lesions and fetal growth restriction are associated with immune abnormalities
(Bezemer et al., 2020; Robertson et al., 2018); collectively these features point toward an
immune basis for a subset of IUFD. While the precise systemic and uterine mucosal
immune pathways mechanistically responsible for IUFD remain elusive, current research
has focused on a role for regulatory T cells (Tregs) in fetal loss.
Tregs are necessary for successful allogeneic mammalian pregnancy (Aluvihare et al.,
2004; Rowe et al., 2011, 2012; Samstein et al., 2012; Shima et al., 2010). Evolutionarily,
the advent of the placenta coincides with CNS1, the FoxP3 enhancer required for
peripheral Treg induction (Samstein et al., 2012). Treg depletion early in gestation or just
prior to mating causes complete fetal loss but Treg depletion in mid-late gestation only
causes occasional loss (Shima et al., 2010; Teles et al., 2013). The role of Tregs in
promoting fetal health in the second half of gestation is unclear.
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Research in immune mechanisms of fetal loss has focused on Tregs with fetal-specific
T cell receptors (TCRs) and how they may interact with other fetal-specific T cells to
maintain tolerance to fetal antigens during pregnancy (Aluvihare et al., 2004; Kahn &
Baltimore, 2010; Rowe et al., 2012). Tregs are thought to contribute to CD8+ T cell
dysfunction in pregnancy as a key mechanism of promoting maternal-fetal tolerance and
hence, preventing fetal loss (Barton et al., 2017; Kinder et al., 2020; Suah et al., 2021;
Tilburgs & Strominger, 2013). While one mechanism of Treg prevention of fetal loss
may be inducing tolerance in anti-fetal T cells, Treg depletion in pregnancy is also
associated with uterine artery dysfunction and shallow placentation (Care et al., 2018;
Robertson et al., 2018; Samstein et al., 2012; Woidacki et al., 2015). This study serves to
address an additional potential mechanism by which Tregs prevent fetal loss: through
modulation of uterine mucosal immune populations.
Mucosal immune cells are critical to the protection and homeostasis of barrier sites and
are integral to both mucosal disease and their treatment (Braga et al., 2019; D. Lin et al.,
2021; Schepper et al., 2018; Yamasaki & Eeden, 2018). Studies on the mucosal immunity
of the female reproductive tract have primarily examined the nonpregnant state. In the
non-pregnant uterus, mucosal immune cells are implicated in pelvic inflammatory
disease, endometriosis, and endometrial cancer and new therapies target these uterine
cells (Brooks et al., 2019; Hogg et al., 2020; Islam et al., 2016). Most studies on the
pregnant uterus have focused on NK cells, which are the most dominant uterine immune
population in early pregnancy (Cappelletti et al., 2020; Erlebacher, 2013). Uterine NK
cells defend against congenital infections, are implicated in early pregnancy loss and
implantation failure, and have been modulated to treat infertility – demonstrating their
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multifactorial roles in pregnancy outcomes (Csabai et al., 2020; Guerrero et al., 2020;
Moffett & Shreeve, 2015; Sheikhansari et al., 2020; Shmeleva & Colucci, 2021).
However, there is a paucity of data on the contributions of mucosal immune cells at the
maternal-fetal interface later in pregnancy, after implantation, or on how these cells may
impact IUFD. We therefore seek to address this knowledge gap and hypothesize that the
pathophysiology leading to IUFD also involves uterine immune cell interactions and that
understanding these local cellular dynamics is critical for developing novel therapeutic
strategies.
The CBA mouse strain has a reproductive phenotype that is currently characterized as
fetal “resorption,” describing a fetal loss pathology with a dark necrotic fetal tissue mass
at an implantation site (Bonney & Brown, 2014). Many studies have demonstrated that
immune interventions, such as maternal injections of cytokines: IL-17, IL-10, TNFa and
GM-CSF (Blois et al., 2004; Chaouat et al., 1995; Clark et al., 2004; W. Xu et al., 2016);
adjuvants: CFA, LPS, poly I:C (Clark et al., 2004; Strassburger et al., 1992; J. Zhang et
al., 2007); or blocking antibodies: anti-CD40L, anti-CTLA-4 and anti-Tim-3 (Li et al.,
2020; S. Wang et al., 2019) alter the rates of fetal loss in CBA mice. However, these
studies target diverse immune pathways and are unable to reveal a clear mechanism
between the systemic intervention and fetal loss phenotype.
To elucidate specific immune mechanisms contributing to the pathogenesis of IUFD,
we utilize the CBA mouse strain. We first rigorously characterized the reproductive
phenotype, interrogated the parental or fetal origin of CBA fetal loss, and examined
tissue-specific immune compositions over multiple gestational time points. We then
queried whether a systemic Treg transfer to the dam would rescue the fetal loss
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phenotype and alter local uterine immune cell composition. Importantly, we
comprehensively explored uterine tissue immune populations through single-cell RNAsequencing (scRNA-seq) of uterine myeloid cells from pregnant CBA mice, comparing
Treg-recipients to saline control mice. We demonstrate that systemic Treg transfer alters
uterine myeloid populations and identify a Trem2+, C1q+, MHC-IIlow uterine
macrophage population that may be critical for pregnancy maintenance and reproductive
health.
Results
CBA mice have multiple aberrant reproductive phenotypes.
We first characterize CBA reproductive phenotypes by comparing CBA pregnancies to
C3H/HeN (C3H) pregnancies, with CBA and C3H females mated to DBA/2 males. C3H
females were used as a control mouse strain because they are close genetic relatives of
CBA mice. Both strains were derived from mating a Bagg albino female and DBA male
and both have the MHC haplotype H-2k (Groner & Hynes, 1980). DBA/2 males were
selected as a mate because they are the most frequently studied mate of CBA females
(Bonney & Brown, 2014)and are allogeneic from CBA and C3H mice, expressing the
MHC haplotype H-2d. To determine the timing of fetal loss, CBA and C3H female mice
were mated to DBA/2 males and sacrificed every two days from E8 – E14. No evidence
of fetal loss was visible at E8 or E10, indicating a mid-late gestation fetal loss phenotype
(Figure 3.1A).
Pregnancies carried by CBA females had higher rates of fetal loss (Figure 3.1B), fewer
viable fetuses (Figure 3.1C), and ultimately smaller litter sizes at term (Figure 3.1D). The
difference in fetal health between C3H and CBA pregnancies is grossly visible by E14
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(Figure S3.1). By late in gestation –despite the smaller litter size, which usually confers
an increase in fetal weight – fetuses from CBA dams weigh less (Figure 3.1E). Fetuses
from CBA dams also have larger placentae (Figure 3.1F) and a smaller fetal:placental
weight ratio (Figure 3.1G) than fetuses from C3H dams, suggesting placental
insufficiency. CBA pregnancies also frequently contain monochorionic diamniotic twins,
rarely present in C3H pregnancies (Figure S3.2A). At E14, these twins may both appear
normal (Figure S3.2B) or one twin may have demised (Figure S3.2C). These data
demonstrate aberrant pregnancy phenotypes in CBA mice beyond simply fetal loss, with
multiple placental abnormalities.
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Figure 3.1: Adverse phenotypes in CBA pregnancy are evident in the second half of gestation. C3H
and CBA dams were timed-mated to DBA/2 sires to compare pregnancy phenotypes. (A) Pregnant females
were sacrificed every two days from E8 – E14 (N = minimum of 4 mice/strain/age) and fetal loss was
recorded. In subsequent experiments, (B) the rate of fetal loss was reported at E14, (C) the number of
viable fetuses was counted at E18, and (D) the number of live pups was counted on postnatal day 1. (E)
Fetal and (F) placental weights were also recorded on E14 and E18 and the (G) fetal-to-placental weight
ratio was calculated. For all datasets, normality was assessed by Shapiro-Wilk test. Differences in the rate
of fetal loss and fetal and placental weights over multiple gestational ages was assessed by two-way
ANOVA, followed by Sidak’s multiple comparison test comparing differences between strains at each
gestational age. Differences between two matings at a single gestational age was analyzed by unpaired t-
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test if normally distributed, or Mann-Whitney test if non-normally distributed. *:p<0.05, **:p<0.01,
***:p<0.001, ****:p<0.0001.

CBA fetal loss is maternal in origin.
To determine the mechanism of CBA fetal loss, we first establish whether the
pregnancy defect is maternal, paternal, or fetal. We characterized the pregnancy
phenotype by mating both male and female CBA mice to other strains of mice (N = 12
different mating pairs) and comparing the rates of fetal loss to core reference strains, such
as C57BL/6 and BALB/c (Figure 3.2A). When CBA male mice sired pregnancies, the
rates of fetal loss were the same as seen in more common strains (median rate: 0%)
(Figure 3.2A). Conversely, when pregnancies were carried by CBA female mice, the
rates of fetal loss were elevated (median rate: 25%) (Figure 3.2A) regardless of paternal
strain. As fetal genotype could influence pregnancy outcome, we controlled for this by
mating CBA females to C3H males and compared rates of fetal loss to C3H females
mated to CBA males. In these pregnancies, the fetal genotypes are the same (CBA x
C3H), but the parentage is reversed. In CBA x C3H pregnancies, carried by CBA
females, fetal loss was greater than in C3H x CBA pregnancies, carried by C3H females,
whether measured as a rate per pregnancy (Figure 3.2B) or as a total count of healthy
versus demised fetuses (Figure 3.2C). These data demonstrate that the reproductive
phenotype of fetal loss is dependent on the maternal genetic/immune status.
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Figure 3.2: Fetal loss in CBA pregnancy is dependent on maternal strain. Timed-matings were
conducted between 5 strains of mice in different mating pairs: C57BL/6, BALB/c, DBA/2, CBA, and
C3H/HeN. (A) Pregnant dams were sacrificed on E14-15 and healthy versus demised fetuses were counted
and reported as a rate of fetal loss. N = minimum of 4 pregnancies/pair. CBA dams were mated with
C3H/HeN sires and C3H/HeN dams were mated with CBA sires, side by side. Dams were sacrificed at E14
and healthy versus demised fetuses were counted and (B) reported as a rate of fetal loss and (C) as a total
count of fetuses. Rates of fetal loss among more than two matings were compared by Kruskal-Wallis test
followed by a post-hoc Dunn’s multiple comparison test comparing fetal loss in C57BL/6 female x
BALB/c male pregnancies to all others. Rate of fetal loss between two matings were compared by MannWhitney test. Fetal counts were compared by Fisher’s exact test. *:p<0.05, **:p<0.01, ***:p<0.001.

Pregnant CBA mice have both systemic and local immunologic differences from C3H
mice.
We comprehensively surveyed CBA and C3H immune cell composition in both local
and systemic compartments to elucidate CBA immune abnormalities in an unbiased
manner. Immune cell composition was first compared in the spleen and uterus of virgin
female CBA and C3H mice. CBA mice have fewer splenic Tregs and macrophages than
C3H mice (Figure 3.3A-B). No differences in immune cell composition were detected in
the uteri of virgin CBA and C3H female mice (Figure 3.3C-D, S3.3).
To determine if there were local immune differences during pregnancy, CBA and C3H
female mice were mated to DBA/2 males and sacrificed every two days from E8 – E14.
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While some local immune populations followed similar trends over gestation between the
strains (Figure 3.3C-D, S3.4), by E14 significant differences were noted in the Treg and
macrophage compartments. Spleen and uterine-draining lymph nodes (uLN) of E14
pregnant CBA mice had fewer Tregs than C3H mice (Figure 3.3E). Pregnant CBA mice
also had fewer macrophages in the spleen, decidua and placenta, and the CBA
macrophages expressed higher levels of MHC-II than C3H macrophages (Figure 3.3F-G).
The elevated MHC-II expression on CBA macrophages was notably significant in local
uterine and decidual macrophages (Figure 3.3G-H). While no quantitative differences in
uterine immune cells were noted between CBA and C3H virgin mice (Figure S3.3), the
immune composition of the specialized uterine and decidual environments during
pregnancy differ between CBA and C3H mice (Figure 3.3B, D-H), supporting a role for
uterine immune cells in the CBA pregnancy defect.
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Figure 3.3: Gestational time course reveals that CBA mice have fewer systemic Tregs and fewer
splenic and uterine macrophages. Timed-matings were conducted with CBA and C3H/HeN dams mated
to DBA/2 sires. Mice were sacrificed every two days from E8 – E14 and the immune composition of the
maternal spleen, uterine-draining lymph nodes (uLN), uterus, decidua, and placentae were analyzed by
flow cytometry. Spleen and uterus from virgin CBA and C3H/HeN females were also analyzed. Immune
cells in virgin mice (left) and over E8-E14 of gestation (right) are shown for (A) splenic Tregs, (B) splenic
macrophages, (C) uterine Tregs, and (D) uterine macrophages. At E14, (E) Treg and (F) macrophage
levels, as well as (G) MHC-II expression on macrophages are reported in multiple tissues. (H)
Representative flow plots of decidual macrophages at E14 of C3H/HeN (left) and CBA (right) pregnancy
gated on non-debris, singlets, live, CD45+, CD19-, Ly6G-, CD11b+, F4/80+ cells. Immune cell differences
in virgin mice were analyzed by unpaired t-test. Gestational time course and comparisons between different
organs were analyzed by two-way ANOVA followed by Sidak’s multiple comparison test comparing
differences between strain. *:p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001.
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Regulatory T cell adoptive transfer prevents fetal loss and decreases MHC-II expression
on decidual macrophages.
Given the systemic deficit of Tregs in both virgin and pregnant CBA female mice and
the known importance of Tregs in pregnancy (Aluvihare et al., 2004; Rowe et al., 2011,
2012; Samstein et al., 2012; Shima et al., 2010), we performed a Treg adoptive transfer.
Tregs were isolated from spleens of E14 pregnant C3H mice by fluorescence-activated
cell sorting (FACS) and 2x105 Tregs in 100µl of PBS were injected into E2 CBA dams.
Control CBA mice received 100µl PBS alone. The quantity and timing of Treg transfer is
based prior studies of Tregs in CBA mice (Idali et al., 2020; J. Wang et al., 2019;
Zenclussen et al., 2005). Maternal Treg transfer increased the numbers of viable over
demised fetuses (Figure 3.4A), decreased the rate of fetal loss at E14 (Figure 3.4B), and
increased the number of viable fetuses at E18 (Figure 3.4C). Treg transfer was not
sufficient to increase fetal weight, decrease placental weight, or improve the
fetal:placental weight ratio (Figure 3.4D-F). These findings suggest that systemic
(maternal) Treg administration modulates a key pathway driving the fetal loss phenotype
but appear insufficient to completely reverse all aspects of the phenotype.
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Figure 3.4: Regulatory T cell adoptive transfer prevents fetal loss. Timed-matings were conducted
between CBA dams and DBA/2 sires. At E2-E3, pregnant CBA dams received retroorbital injections of
either 2x105 Tregs isolated from the spleen of pregnant C3H/HeN dams or PBS. Mice were sacrificed at
E14 and (A) healthy versus demised fetuses were counted and (B) reported as a rate of fetal loss. In
subsequent experiments mice were sacrificed at E18 and (C) viable fetuses were counted. The weights of
(D) healthy fetuses and (E) their placentae were measured at E14 and E18 and reported as a (F) ratio of
fetal weight to placental weight. Count data (A) was assessed by fisher’s exact test, fetal loss (B) was
assessed by Mann-Whitney test, and viability (C) was assessed by unpaired t test. Weights (D, E, F) were
assessed by two-way ANOVA. *:p<0.05, **:p<0.01.

To assess how systemic administration of immune cells might alter immune
composition in the reproductive tissues, we analyzed both systemic and local tissues to
determine if the systemic injection of Tregs was able to alter local immune populations in
the uterus, decidua, and placenta. We hypothesized that Treg transfer may specifically
alter uterine macrophages, given that the primary difference we found between CBA and
C3H uterine immune cells was in macrophage expression of MHC-II (Figure 3.3G), and
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Tregs are known to decrease MHC-II on macrophage cell membranes (Tiemessen et al.,
2007). Pregnant CBA mice, having received Tregs or saline (controls) on E2, were
sacrificed on E14, 12 days after the initial injection. Tregs were increased in the uLNs of
Treg-recipients over controls (Figure 3.5A). Macrophages were increased in Tregrecipients over controls in maternal blood, but not in the uterus or decidua (Figure 3.5B).
Given the lack of quantitative changes in broad immune cell types local to the maternalfetal interface, we then evaluated macrophage subsets and expression of markers that
impact macrophage function. Decidual macrophages from Treg-recipients had reduced
expression of MHC-II, similar to what is observed in decidual macrophages from healthy
C3H mice (Figures 3.5C, 3.3G). We hypothesized that Treg transfer would induce an
‘M2’-like macrophage phenotype, as has been reported in mice with healthy pregnancy
(Meng et al., 2017), so we analyzed CD206+ MHC-IIlow macrophages, but did not
identify a difference (Figure 3.5D). We then investigated signs of macrophage activation
– specifically looking at CD80 and CD86 expression. Treg-recipient mice had more
CD86- MHC-II- macrophages in their blood, uterus, and decidua than controls (Figure
3.5E). Decidual macrophage expression of CD86 and MHC-II is visualized in
representative flow plots (Figure 3.5F). These results support our hypothesis that a
systemic Treg transfer can alter local uterine and decidual macrophages – changing the
macrophage phenotype to be more similar to those from healthy C3H mice.
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Figure 3.5: Regulatory T cell adoptive transfer alters the phenotype of uterine macrophages. At
E14 following Treg transfer, maternal blood, uterine draining lymph nodes (uLN), uterus, and decidua were
collected and analyzed for immune cell composition by flow cytometry including for (A) regulatory T
cells, (B) total macrophages (C) macrophage expression of MHC-II, (D) M2 macrophages, and (E) CD86MHC-II- macrophages. (F) Representative flow plots of CBA decidual macrophages at E14 after Treg
transfer (right) and control PBS (left) gated on non-debris, singlets, live, CD45+, CD19-, CD4-, Ly6G-,
CD11b+, F4/80+ cells. Two-way ANOVA followed by Sidak’s multiple comparison test was used to
compare mice treated with PBS versus Tregs in different organs. p<0.05, **:p<0.01, ***:p<0.001. N=3
mice/group.

Single-cell RNA-sequencing of uterine CD11b+ cells identifies an increase in an uterine
macrophage subset following Treg transfer.
Our initial Treg transfer demonstrated that a single systemic injection early in
pregnancy (E2) could change uterine myeloid populations and sustain those changes for
at least 12 days. To investigate specific changes in the uterine myeloid cells induced by a
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maternal Treg injection, we performed single-cell RNA-sequencing (scRNA-seq) on
CD11b+ cells isolated from the uteri of 3 Treg-recipient mice and 3 PBS-injected control
mice. The combined sequenced cells were visualized in 2D space by UMAP and 15
clusters were identified (Figure 3.6A). Cluster identities were determined by expression
of cell type defining genes (Figure 3.6B). Seven clusters expressed Adgre1 but not Ly6c2,
indicating they are in the macrophage/monocyte lineage but not classical monocytes:
clusters 0, 1, 4, 9, 10, 11, and 12 (Figure 3.6B). Those macrophage clusters were further
analyzed for differentially expressed genes (Figure 3.6C). Within the same cell type
cluster, there was little differential gene expression between the cells from Treg-recipient
or PBS-injected control mice (Figure S3.5). However, Treg transfer influenced the
proportions of each cell type present in the uterus, specifically increasing cluster 0
Trem2+ macrophages (p=2.2e-12) and decreasing cluster 3 neutrophils (p=3.6e-12)
(Figure 3.6D).
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Figure 3.6: Single cell RNA sequencing of uterine CD11b+ cells identified an increase in Trem2+
macrophages and a decrease in CCL3+ neutrophils following Treg transfer. (A) Seurat UMAP
clustering of uterine CD11b+ cells combined from all 6 mice identified 15 cell subsets. (B) Cell type of
each cluster was identified by expression of cell type-defining genes: Adgre1 for macrophages and
monocytes, Ly6c2 for monocytes, S100a9 for neutrophils, Cd209a for dendritic cells, Nkg7 for NK cells,
and Epcam for epithelial cells. (C) Clusters that were Adgre1+ but Ly6c2- (0, 1, 4, 9, 10, 11, 12) were
further identified by their individual gene signatures. The top 5 differentially expressed genes for each of
those clusters are shown in a heatmap. (D) The cellular make up was differentiated between mice that
received Tregs versus control mice that received PBS and analyzed by Fisher’s Exact Test. Cluster 0 and
cluster 3 had significantly different proportions in the Treg transfer recipient mice. Abbreviations: MP:
macrophage; NP: neutrophil; AA: alternatively activated; Mono: monocyte; DC: dendritic cell; CK:
cytokine. Mo: monocyte; NK: natural killer cell; Epi: decidual epithelial cell.

Furthermore, Treg transfer shifted the ratio of the two largest groups of uterine
macrophages: cluster 0 and cluster 1. Treg recipients had a 55.2% higher ratio of clusters
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0:1 than PBS-injected control mice (Figure 3.7A). Cluster 1 has increased differential
expression of MHC-II and related genes (i.e. H2-Aa, H2-Ab1, H2-Eb1, Cd74, H2-DMa,
H2-DMb1) when compared to cluster 0, which are visible in the top left corner of the
volcano plot (Figure 3.7B). This contrast in MHC-II expression between cluster 0 and
cluster 1 can be visualized by examining expression of the class II gene H2-Aa between
cluster 0 and cluster 1 (Figures 3.7C-D).
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Figure 3.7: An MHC-II low macrophage cluster is enriched in the uteri of Treg-recipient mice. (A)
Treg recipient mice have an increased ratio of cluster 0 to cluster 1 cells compared to control mice. (B)
Volcano plot compares differential gene expression of cluster 0 and cluster 1. (C) Feature plot show
expression of H2-Aa in clusters 1 and 2. (D) Violin Plots enumerate H2-Aa expression in clusters 1 and 2.

Regulatory T cell transfer increases uterine macrophages that have a similar
transcriptome to tumor associated macrophages.
To investigate potential functions of the cluster 0 uterine macrophages, we conducted
pathway analysis on the top 50 cluster defining genes (Zhou et al., 2019). Cluster 0
macrophages are enriched for gene pathways including cell junction disassembly,
migration, and response to TGFb (Figure 3.8A). The top 50 cluster 0-defining genes
encode proteins with potential interactions: lysosomal proteins and the C1q complex
(Figure 3.8B), suggesting a functional role for complement and lysosomes in this cell
type. To further analyze potential functions of cluster 0 macrophages, we compared their
gene set to known mouse myeloid gene signatures. Gene lists were compiled from
scRNA-seq experiments on mouse myeloid cells into a single gene matrix of 123 gene
lists (Antunes et al., 2021; Burl et al., 2018; Cochain et al., 2018; Harasymowicz et al.,
2021; Jaitin et al., 2019; Katzenelenbogen et al., 2020; Keren-Shaul et al., 2017; Mildner
et al., 2017; E. C. E. Wang et al., 2019; Weinberger et al., 2020; Xiong et al., 2019; L.
Zhang et al., 2020; Zilionis et al., 2019). 47 of the gene lists were upregulated in a ranked
list of all genes expressed by cluster 0 uterine macrophages. The normalized enrichment
score (NES) of each of these 47 gene lists was plotted against the nominal p-value of the
enrichment (Figure S3.6). Of those upregulated gene lists, 10 had significant nominal pvalues of <0.01 (Figure 3.8C). The gene set with the highest NES and lowest false
discovery rate (FDR) q-value was one for tumor-associated macrophage 2 (TAM2) from
a mouse model of glioblastoma multiforme (GBM) (Figure 3.8C, purple circle). The
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similarity between the TAM2 gene set and our cluster 0 macrophages can be visualized
by an enrichment plot (NES = 1.62, FDR q-value = 0.001) (Figure 3.8D).
Leading edge analysis was performed on the 10 gene lists enriched in cluster 0
macrophages with a p-value <0.01 to search for a conserved core gene signature among
these macrophage subtypes (Figure 3.8E). Of these leading-edge genes, seven were
present in 9 out of 10 gene lists: C1qa, C1qb, C1qc, Grn, Itgb5, Lgmn, and Trem2, with
Trem2 having the highest expression values in cluster 0 (Figure 3.8E). This analysis
suggests an important conserved role for those 7 genes in this macrophage subset.

57

Figure 3.8: Cluster 0 uterine macrophages are enriched for similar sets of genes as tumorassociated macrophages. Metascape pathway analysis was completed for the top 50 differentially
expressed genes in cluster 0. (A) The top 20 enriched pathways are listed. (B) Included in those top 50
genes are 9 genes encoding interacting proteins: 6 lysosome proteins and 3 C1q complex proteins.
Published gene lists from single-cell RNA sequencing of mouse myeloid cells were compiled into a gene
matrix. (C) 10 gene lists had enrichment scores with p-values less than 0.01. (D) A gene list for tumor
associated macrophages in mouse model of glioblastoma3 (TAM2) was most enriched in cluster 0 (purple
circle). Leading edge analysis was performed on the ten gene lists in 7C. (E) Genes that appeared in the
leading edge of 5 or more of the 10 gene lists are shown in a heatmap. Color shows range of expression
scores in cluster 0 from 0 – 500. The genes and gene lists underwent independent hierarchical clustering
shown on each axis. Abbreviations: M : macrophages; TAM: tumor associated macrophage; GBM:
glioblastoma multiforme; AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; DAM: disease
associated macrophage; MG: microglia; MP: macrophage; LC: lung cancer.
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Trem2+ MHC-IIlow uterine macrophages are increased in the uterus of mice with healthy
pregnancies and are evident in human decidua.
As our scRNA-seq analysis was conducted on CBA mice, which have a demonstrated
reproductive phenotype with fetal loss, we next determined whether our cluster 0 Trem2+
MHC-IIlow uterine macrophages were present in mice and humans with normal
pregnancies. The uterine immune composition of IUFD-prone CBA and healthy C3H
pregnant mice was analyzed on E14 by flow cytometry. A clear population of Trem2+
MHC-IIlow/neg macrophages was identified (Figure 3.9A). C3H mice, without any known
reproductive pathology, had 44.8% more uterine Trem2+ MHC-IIlow macrophages
compared to the IUFD-prone CBA mice (Figure 3.9B). Uterine macrophages from C3H
mice expressed 1.7-fold more Trem2 than CBA uterine macrophages (Figure 3.9C),
suggesting a role for Trem2+ uterine macrophages in the C3H mice with healthy
pregnancies.
Given the biologic differences between mice and humans, we next assessed whether
the identified macrophage subtype in the uteri of CBA pregnancies was present in normal
human decidua. Vento-Tormo, et al. published scRNA-seq data from tissues of the
maternal-fetal interface of human pregnancies, including decidua from elective
terminations of normal pregnancies (Vento-Tormo et al., 2018). Using gene set
enrichment analysis, we compared the macrophage and monocyte populations from our
murine gene set to those in the published human gene set (Figure 3.9D). The human
decidual macrophage 2 (dM2) gene signature was significantly enriched in our cluster 0
Trem2+ uterine macrophages (Figures 3.9D-E). The top five core enriched genes from
Trem2+ mouse macrophages and dM2 human macrophages were MS4A7, TREM2,
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CD81, CX3CR1, and C1QA and protein interaction predictions from the core enriched
genes included those for leukocyte chemotaxis, collagen catabolism, and the C1q
complex (Figure 3.9F). Of the core enriched genes between the human and mouse
decidual macrophages, 70% (21 of 30) were also present in the leading-edge genes
enriched in the mouse gene sets (Figure 3.9E). Thus, the core enriched genes between
Trem2+ mouse uterine macrophages and human dM2s resembles the conserved gene
signature among related mouse macrophages in different tissues (Figure 3.9E), further
supporting that this group of genes are critical to the function of these uterine
macrophages and suggesting interspecies conservation of this cell type in pregnancy.
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Figure 3.9: Cluster 0 macrophages are increased in the uterus of mice with healthy pregnancies
and are evident in normal human decidua. Cluster 0 macrophages were identified by flow cytometry as
Trem2+ MHC-II low macrophages. (A) Representative flow plots show uterine macrophages from E14
pregnant C3H/HeN (healthy) and CBA (IUFD-prone) dams mated with DBA/2 sires. Flow plots are gated
on non-debris, singlet, live, CD45+, CD3-, Ly6G-, CD11b+, F4/80+ cells. (B) The frequency of Trem2+
MHC-II low macrophages and (C) the overall macrophage Trem2 expression was measured. Published data
of single-cell RNA sequencing from normal human decidua identified 3 decidual macrophages and one
maternal monocyte cluster. (D) The enrichment score of each mouse cluster gene set for each human cell
gene list is graphed in a heat map. (E) Gene set enrichment plot for human dM2 gene set enrichment in
mouse uterine cluster 0 macrophages. (F) Core enriched genes between dM2 and cluster 0 macrophages
included genes for potentially interacting proteins in chemotaxis, collagen catabolism, and c1q complex.

Discussion
We have identified a maternal-derived mechanism of fetal loss associated with both a
deficit in maternal systemic Tregs and aberrant uterine myeloid cells. These data confirm
our hypothesis that local immune cells at the maternal-fetal interface are mechanistically
involved in pregnancy outcomes. Furthermore, for potential translational impact, these
data demonstrate that a systemic intervention to the mother can alter tissue-specific
immune populations. Using scRNA-seq, we discovered a novel Trem2+ C1q+ MHC-IIlow
uterine macrophage population that may be necessary for optimal reproductive health.
Collectively, these data demonstrate a novel mechanism by which Tregs influence
pregnancy outcomes through modulation of the uterine immune composition, particularly
macrophages, which impacts fetal health.
The CBA strain has been utilized to study recurrent pregnancy loss (RPL) (Bertoja et
al., 2005; Cheng et al., 2021; Dixon et al., 2006; He et al., 2018; Hosseini et al., 2020; Li
et al., 2020). However, there have been concerns that the reproductive phenotype of CBA
pregnancy loss does not sufficiently recapitulate human RPL (Bonney & Brown, 2014).
Our rigorous approach enabled us to characterize the reproductive phenotype of CBA
pregnancy more comprehensively: gestational time course data show that fetal loss in the
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CBA model is post-implantation and is specific to the second half of pregnancy and is
therefore more similar to IUFD than RPL (Figure 3.1A). This conclusion is consistent
with findings of uterine and placental vasculature abnormalities in mid-gestation CBA
mice, showing that the uterine arteries have small lumen-to-wall ratios and placentae
have evidence of thrombosis and fibrin deposition (Dixon et al., 2006; Hosseini et al.,
2020). Placentae from human IUFDs often have similar findings and placental pathology
is considered the most useful test to help determine causes of IUFD (Page et al., 2017).
Therefore, our data on the timing of fetal loss (Figure 3.1A) and placental abnormalities
(Figures 3.1E-G, S3.2) in the CBA strain is consistent with human IUFD.
Treg adoptive transfers have been previously performed on CBA mice with a focus on
the impact of Tregs on early implantation, Treg antigen-specificity, or in vitro Treg
induction strategies (Idali et al., 2020; J. Wang et al., 2019; Woidacki et al., 2015;
Zenclussen et al., 2005). Although we use Tregs from C3H mice rather than CBA mice,
our findings reproduce the existing data that Tregs reduce the rate of fetal loss in CBA
mice. These prior studies have primarily focused on the function of Tregs themselves:
cytokine production, response to paternal alloantigen, suppressive activity, or epigenetic
modifications (Idali et al., 2020; J. Wang et al., 2019; Zenclussen et al., 2005); or Treg
impact on implantation (Teles et al., 2013; Woidacki et al., 2015). In contrast, we
interrogated how an increase in maternal Treg number would affect reproductive tissues
by examining tissue resident immune cells at the time of fetal loss. Decidual macrophage
polarization has been shown to impact pregnancy outcomes, with more
immunosuppressive or “M2-like” macrophages associated with healthy pregnancy
(Baines et al., 1997; Gustafsson et al., 2008; Meng et al., 2017; Y. Zhang et al., 2018).
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Tregs are known to induce a pro-phagocytic, anti-inflammatory phenotype in
macrophages (Proto et al., 2018; Tiemessen et al., 2007). Our data provides a mechanistic
link between Tregs and uterine macrophage polarization.
The Trem2+ uterine macrophages increased by Treg transfer highly transcribe the
TGFb receptor gene (Tgfbr1) and “cellular response to transforming growth factor beta
stimulus” is one of the key pathways identified in their gene signature (Figure 3.8A).
These findings suggest that Tregs may communicate to Trem2+ uterine macrophages via
TGFb. Low expression of MHC-II implies that Trem2+ uterine macrophages are not
acting upon T cells or presenting antigen to the Tregs. Moreover, the mechanism of CBA
fetal loss is likely to be independent of fetal antigen, given that CBA syngeneic
pregnancies still have elevated rates of fetal loss (Figure 3.2A). These data support an
antigen-independent manner of Treg manipulation of macrophage phenotype, leading to
improved pregnancy outcomes.
The Trem2+ uterine macrophages identified in this study transcriptionally resemble
tumor-associated macrophages (TAMs). Trem2+ macrophages in tumors are
immunosuppressive and promote tumor survival (Katzenelenbogen et al., 2020), and
likewise Trem2+ uterine macrophages may also be immunosuppressive and promote fetal
survival. The process of placentation, of trophoblast invasion into the uterine vasculature,
has been fittingly described as akin to tumor metastasis into tissue vasculature (Mor et al.,
2017)and therefore Trem2+ uterine macrophages may be necessary for successful
placentation.
Another potential role of Trem2+ uterine macrophages is to clear cellular debris, which
accumulates during placentation (Sharp et al., 2010). Trem2 in microglia functions to
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prune synapses and clear dying neurons (Deczkowska et al., 2020; Hsieh et al., 2009).
The uterine Trem2+ macrophages were enriched for lysosomal protein genes and C1q
genes (Figures 3.8B, 3.9F), which imply that the role of this cell subset involves
phagocytosis and removal of unwanted material (Figures 3.8B, 3.9F). C1q genes
appeared as a core signature when performing gene set enrichment analysis on our cluster
0 uterine macrophages with other mouse macrophage gene sets and human decidual
macrophage gene sets (Figures 3.7B, 3.8F) suggesting a interspecies conserved role of
C1q in the function of this macrophage subtype. C1q-deficient mice have pathologic
pregnancies with fetal loss, insufficient trophoblast invasion, and kidney damage
(Agostinis et al., 2010; Singh et al., 2011). In human pregnancy, endovascular
trophoblasts express C1q-receptor and bind to C1q expressed on the surface of decidual
endothelial cells (Agostinis et al., 2010). Given trophoblast expression of C1q-receptor,
C1q expression in decidual cells allows for direct contact with trophoblasts and appears
necessary for adequate remodeling of uterine spiral arteries.
Because of some biological differences between murine and human pregnancy (e.g.
multifetal pregnancy, short gestation), there are some limitations to the use of the CBA
mouse strain in investigating reproductive outcomes. However, noting these limitations,
mouse models have provided critical insight into mechanisms of reproduction and
parturition (Burd et al., 2011; Elovitz et al., 2003; Rowe et al., 2012; Suah et al., 2021).
Additionally, mechanistic studies on reproductive tissues over gestation are not feasible
in humans and collection of fetal and maternal tissues from mid-late gestation human
pregnancies is not ethical. While tissues may occasionally be available after diagnosis of
an IUFD, these tissues cannot be informative as to the tissue or immune dynamics that
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occurred prior to the loss. Notably, the transcriptional similarity between human and
mouse decidual macrophages (Figures 3.9D-F), suggests a conserved function across
species. An additional limitation is that our scRNA-seq data is only from one time point
during gestation. While this gestational age was carefully chosen based on our time
course experiments and the occurrence of the reproductive phenotype in the CBA strain,
other key differences induced by Tregs prior to E15 might have been missed. Future
studies could address the precise changes to uterine immune cells following Treg
injection.
To our knowledge, this is the first study to report findings from scRNA-seq on the
myeloid populations of a pregnant mouse uterus, and thus contributes to the growing field
of reproductive immunology. These results build upon research that has characterized
specific immune cells present at the maternal fetal interface using flow cytometry,
immunohistochemistry, and cell type-deficient mice (Erlebacher, 2013; Mor et al., 2017),
by adding unbiased and thorough transcriptomic information. Single-cell experiments
have been conducted on human tissue from the maternal-fetal interface (Pique-Regi et al.,
2019; Vento-Tormo et al., 2018), and these studies have provided valuable insight into
the normal immune composition of the decidua and placenta. However, human studies
are limited to postpartum or aborted tissues, limiting their application to IUFD and other
events in late gestation.
Pregnancy functions as an immunologic challenge to the maternal immune system, a
challenge that exposes a pathology in the CBA mouse strain. The uteri of virgin CBA and
C3H mice have no difference in immune composition (Figure S3.3); the differences in
immune composition and ultimate reproductive phenotype develop over gestation (Figure
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3.3). Our findings demonstrate that the decidua is a unique immunologic niche, requiring
a specific balance of immune subtypes for healthy pregnancy. The maternal origin of the
mechanism of IUFD discovered in this study, dependent on decidual immune
populations, indicates a role for the decidua in the regulation of placentation and fetal
health. Future studies of IUFD and other reproductive pathologies should consider
decidual immune subsets as fundamental determinants of reproductive health.
While there have been large cohort studies performed to address IUFD, there remains
little mechanistic data on human IUFD (Parker et al., 2011). This study of immunologic
mechanisms of IUFD points to targetable pathways for therapeutics, and future studies
could leverage these findings to help predict and prevent future IUFDs. Trem2 agonists
are already in preclinical studies for treating Alzheimer’s Disease and other
neurodegenerative disease (Price et al., 2020) and could be repurposed for reproductive
disorders. Additionally, recombinant human C1q that promotes phagocytosis without
complement activation has been evaluated in vitro for reprogramming macrophages
(Espericueta et al., 2020). Our data most clearly suggest a cell-based therapy by
establishing that a single systemic Treg injection can have a lasting functional impact on
tissue resident immune cells – a finding with implications beyond reproductive
pathologies to all disease caused by tissue-specific immune populations.
Methodology
Animals: Timed-pregnant mice were mated in our mouse colony and vaginal plugs
were checked to confirm copulation. Plugged females were removed from male cages.
Mice were euthanized by CO2 at the indicated gestational age. All animal care and use
procedures are approved by the University of Pennsylvania IACUC.
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Tissue Collection: At the indicated gestational age, mice were euthanized, and tissues
were collected into and washed with 10% charcoal-stripped fetal bovine serum (FBS;
Gemini Bio, Sacramento, CA) in Hank’s balanced salt solution (HBSS) on ice. Maternal
spleen and uterine-draining para-aortic lymph nodes (uLN) were collected. The uterus
was bisected and gestational sacs with fetal membranes and placentae were removed. The
decidua was then scraped from uterus with a glass microscope slide into HBSS + 10%
FBS on ice. Membranes were removed from the placenta and the placenta and uterus
were washed in HBSS + 10% FBS on ice. Tissues were immediately processed into a
single cell suspension for flow cytometry.
Single Cell Suspension: Preparation of tissues for flow cytometry follows a protocol
established with the placenta (Lewis et al., 2018). Placentae and uterus were minced into
2mm pieces, suspended in 5ml of digest solution (HBSS + 10% FBS + 1mg/ml
Collagenase IV, Gibco, Gaithersburg, MD), and incubated in a 37°C water bath for 30
minutes. Placentae and uterus (post-digest treatment), maternal spleens, uLN, and
decidua were mechanically pressed through a 70µm cell strainer. The strainer was rinsed
with 10ml of HBSS and strained cells were passed through a 40µm cell strainer into a
50ml conical tube. Cells were centrifuged at 1500rpm, 4°C for 10 minutes. Red blood
cells were eliminated from tissues by suspension in 3ml of ACK lysing buffer (Gibco,
Gaithersburg, MD) and incubation at room temperature for 10 minutes. ACK-treated
cells were rinsed in 10ml of HBSS and centrifuged at 1500rpm, 4°C for 5 minutes. Single
cell suspensions from maternal spleen, uLN, decidua, uterus, and placenta were
suspended in 1ml of FACS buffer (PBS + 2% FBS + 20µM EDTA) and transferred into
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5ml round-bottom tubes through 35µm filter caps. Cells were stored on ice until ready for
staining.
Flow Cytometry Staining: Cells were transferred to a 96-well round-bottom plate for
staining, washed with PBS, and the plate was centrifuged at 1500rpm, 4°C for 5 minutes.
Cells were resuspended in Live/Dead Fixable Aqua (Invitrogen, Waltham, MA) diluted
1:1000 in PBS and incubated for 30 minutes at 4°C in the dark. Cells were washed twice
with FACS buffer, centrifuging the plate between washes at 1500rpm, 4°C for 5 minutes.
Cells were then resuspended in an extracellular antibody mix and incubated for 30
minutes at 4°C in the dark. Extracellular antibody mixes included: anti-CD3e-APC-Cy7,
anti-CD3e-BV785, anti-CD4-BV605, anti-CD4-PE-Cy7, anti-CD11b-PE, anti-CD11bPerCP-Cy5.5, anti-CD11c-PE-Cy7, anti-CD19-APC, anti-CD19-APC-Cy7, anti-CD45BV711, anti-CD49b-PacificBlue, anti-CD64-PE, anti-CD86-AF700, anti-CD122-FITC,
anti-F4/80-FITC, anti-Ly6C-APC-Cy7, anti-Ly6G-PerCP-Cy5.5, anti-MHC-II-BV785,
anti-TCRg-PerCP-Cy5.5, anti-Tim3-APC, (BioLegend, San Diego, CA); anti-CD8aAPC.efluor780, anti-CD80-SB436, anti-CD206-PE-Cy7, anti-SiglecF-SB600
(eBioscience, San Diego, CA); anti-CD49a-BV605, anti-CD74-BV605 (BD Biosciences,
San Jose, CA); anti-Trem2-APC (R&D Systems, Minneapolis, MN). Cells were washed
twice with FACS buffer, centrifuging between washes at 1500rpm, 4°C for 5 minutes.
Cells were resuspended in fixation/permeabilization reagent (Transcription Factor
Staining Buffer Set, eBioscience, San Diego, CA) and incubated for 30 minutes at 4°C in
the dark. Cells were washed twice with permeabilization buffer (Transcription Factor
Staining Buffer Set, eBioscience, San Diego, CA), centrifuging at 2000rpm, 4°C for 5
minutes between washes. Cells were resuspended in anti-FoxP3-PE (eBioscience, San
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Diego, CA) diluted 1:300 in permeabilization buffer and incubated for 30 minutes at
room temperature in the dark. Cells were washed twice with permeabilization buffer,
centrifuging at 2000rpm, 4°C for 5 minutes between washes. Cells were then
resuspended in FACS buffer and transferred into 5ml round-bottom tubes through 35µm
filter caps and stored at 4°C in dark until analyzed by an LSR-II flow cytometer (BD
Biosciences, San Jose, CA).
Treg Adoptive Transfer: Spleens were harvested from E13-15 pregnant C3H/HeN mice
mated to DBA/2 male mice and processed into a single cell suspension as noted above.
CD4+ cells were isolated from splenic cells using a CD4+ T Cell Isolation Kit, mouse
(Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer’s
instructions. Cells were transferred into 5ml round-bottom tubes through 35µm filter
caps, and centrifuged at 300xg, 4°C for 10 minutes. Cells were washed with FACS buffer
and centrifuged again. Cells were then stained with extracellular antibody mix: anti-CD8APC (1:400), anti-CD4-PacificBlue (1:400), and anti-CD25-PE/Dazzle (1:200)
(BioLegend, San Diego, CA) in FACS buffer for 30 minutes, 4°C, dark. Cells were
washed twice with FACS buffer, centrifuging at 300xg, 4°C for 10 minutes between
washes. Cells were resuspended to 2 x 107 cells/ml of FACS buffer. Cells were then
sorted by the Penn Flow Cytometry Core staff on a BD FACSAria cell sorter (BD
Biosciences, San Jose, CA). Collected Tregs were gated on lymphocytes, single cells,
CD8-, CD4+, CD25high. These cells were sorted into RPMI media with 50% FBS,
centrifuged at 400xg, at 4°C for 10 minutes and washed with PBS. Tregs were
resuspended to 2x106 cells/ml in sterile PBS. Timed-pregnant E2 CBA mice mated with
DBA/2 males were anesthetized by isoflurane and then received 100µl of the Treg
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suspension (2x105 Tregs) or 100µl of sterile PBS by retro-orbital injection. CBA mice
receiving Tregs or PBS injections were co-housed until sacrifice on E14 or E18. Results
are combined from 2-3 experiments at each time point with N=3-5
dams/group/experiment.
Isolating CD11b+ Uterine Cells: Uteri were harvested from E15 timed-pregnant CBA
mice that had received a Treg adoptive transfer or PBS injection on E2 (N=3/group) and
processed into a single cell suspension as noted above. Uterine cells were then
resuspended in 1ml of MACS buffer and CD11b+ cells were isolated with CD11b+
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer
instructions. Eluted CD11b+ cells were centrifuged at 300xg, at 4°C for 10 minutes. Cells
were then resuspended in Live/Dead Fixable Aqua (Invitrogen, Waltham, MA) diluted
1:1000 in PBS and incubated for 30 minutes at 4°C in the dark. Cells were rinsed twice
with FACS buffer, centrifuging at 300xg, 4°C for 5 minutes between washes. Cells were
then stained with the following extracellular antibody mix, all diluted 1:400 in FACS
buffer: anti-CD45-SB702 (eBioscience, San Diego, CA); anti-CD11b-PE, anti-CD3eAPC-Cy7, and anti-CD19-APC.Cy7 (BioLegend, San Diego, CA). Cells were incubated
for 30 minutes at 4°C in the dark, washed twice with FACS buffer, centrifuging between
washes at 300xg, 4°C for 5 minutes. Cells were resuspended to 1x106 cells/ml in FACS
buffer. Cells were then sorted by the Penn Flow Cytometry Core staff on a BD FACSAria
cell sorter (BD Biosciences, San Jose, CA). Collected cells were gated on live, singlet,
CD45+, CD11b+ cells and sorted into 50% FBS + 50% PBS. 15,000 collected
cells/sample were spun down and resuspended in 15µl sterile PBS and brought to the
University of Pennsylvania Next Generation Sequencing Core.
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Single-cell RNA-Sequencing: Library preparation and sequencing was performed by the
University of Pennsylvania Next Generation Sequencing Core. Cell libraries were
prepared using 10X Genomics Single Cell Controller and libraries were sequenced on an
Illumina HiSeq 2500. Transcriptomic matrices were created with 10X Genomics’ Cell
Ranger Single Cell Software Suite 3.1.0. Raw base call files from the HiSeq 2500
sequencer were demultiplexed with the Cell Ranger “mkfastq” pipeline into libraryspecific FASTQ files. All library-related FASTQ files were subsequently transformed
into count matrices with Cell Ranger’s “count” pipeline vs genome reference mm10-3.0.0
(Ensembl 93). The retained reads were quantified and used to generate feature-barcode
matrices.
Seurat Analysis: Resulting matrices for each sample (N=3/group) were merged into a
single object with the merge function in Seurat version 3.1.5 (Stuart et al., 2019). Within
this dataset, cells with more than 200 genes and less than 2500 genes were retained,
provided the cell did not express more than 10% of genes derived from the mitochondria.
The reduced dataset was then normalized and scaled using Seurat default methods.
UMAP clustering was performed using Seurat and gene lists for each cluster were created
using “FindConservedMarkers.” Seurat was also used to identify differentially expressed
genes in each cluster between PBS and Treg-recipient mice using the “FindMarkers”
command.
Gene Set Analysis: Gene signatures for each UMAP cluster were analyzed by the Gene
Set Enrichment Analysis (GSEA) application from the Broad Institute (Subramanian et
al., 2005). Gene signatures were compared to gene matrices from the Molecular
Signatures Database, including hallmark gene sets, ontology gene sets, and immunologic
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signature gene sets. Very few of these gene sets were enriched in the clusters of interest,
so a gene matrix was created. Gene lists were compiled from papers using scRNAsequencing on mouse myeloid cells published in the last 5 years, where full gene lists
were published in supplementary materials (rather than raw sequencing data). A single
gene matrix was created with these 123 gene lists and was compared to the gene
signatures from UMAP defined clusters with the Broad GSEA application (version
4.1.0). Metascape pathway analysis was also used to identify cellular pathways for each
cluster, specifically by searching the top 50 cluster defining genes (Zhou et al., 2019).
Analysis of Human Dataset: Droplet-based single-cell data from Vento-Tormo, et al.
was downloaded from the EMBL-EBI ArrayExpress database (E-MTAB-6701) (VentoTormo et al., 2018). Feature-barcode matrices and annotation level data was read into the
R computing environment. The R package, Seurat, was used for secondary analysis of the
external dataset (Stuart et al., 2019). Briefly, cell type annotations were used for
grouping/differential expression analysis using dM1, dM2, and dM3 cell types.
Differentially expressed gene lists were generated using a Wilcoxon rank sum test.
Adjusted p-values were based on a Bonferroni correction using all features in the dataset.
Statistical Analysis: Prism (GraphPad, San Diego, CA) was used for statistical
analyses. All datasets were analyzed for normality by Shapiro-Wilk test. Non-normally
distributed data with two groups was analyzed by Mann-Whitney test. Normally
distributed data with two groups was analyzed by unpaired student’s t-test, with Welch’s
correction applied if the two groups differed in variance by F test. Time course data was
analyzed by two-way ANOVA, followed by post-hoc Sidak’s multiple comparison test
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comparing CBA to C3H immune cells at each gestational age. Proportion data was
analyzed by Fisher’s Exact test.

Supplemental Figures

A.

B.

Figure S3.1: CBA pregnancies have higher rates of fetal loss than C3H/HeN pregnancies. Photographs
of intact uteri from (A) C3H/HEN and (B) CBA timed-pregnant mice at E14, both mated to DBA/2 males.

Figure S3.2: CBA pregnancies frequently contain monochorionic twins. C3H and CBA female mice
were mated to DBA/2 males and sacrificed at E14 of pregnancy. (A) The presence of at least one
monochorionic diamniotic twin was noted. (B) Representative photo of E14 twins from CBA pregnancy
with amniotic sacs removed. (C) Representative photo of E14 twins from CBA pregnancy with one normal
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(left) and one demised (right) twin. Difference in twin frequency was assessed by Fisher’s Exact Test.
*:p<0.05.

Figure S3.3: Uteri from virgin CBA and C3H/HeN mice show no difference in cellular
immunologic composition. Healthy virgin CBA and C3H mice were sacrificed in estrus. Uterine immune
cells were quantified by flow cytometry: (A) CD4+ T cells, (B) CD8+ T cells, (C) B cells, (D) NK cells,
and (E) neutrophils. No difference between immune populations in CBA and C3H mice was found by
unpaired t-test.
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Figure S3.4: Immune populations at the maternal-fetal interface in CBA and C3H pregnancies.
CBA and C3H female mice were mated to DBA/2 male mice. Mice were sacrificed every two days from
E8 – E14 and immune cells in the (A) uterus, (B) decidua and (C) placenta were assessed by flow
cytometry. At E8 there were too few decidua cells for analysis so (B) decidual cells are only quantified
from E10-E14. Quantitative differences between immune populations over gestation was assessed by twoway ANOVA, followed by Sidak’s multiple comparison test comparing CBA to C3H rates of loss at the
same gestational age if ANOVA was significant. No significant differences were detected by Sidak’s test.
N=4 mice/strain/gestational age.
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Figure S3.5: Differentially expressed genes between Treg-recipient and control mice. Single-cell
RNA sequencing was performed on CD11b+ cells from the uteri of 3 Treg-recipient mice and 3 PBS
control mice. Overall, there were few differences in gene expression between (A) total Treg and PBS cells,
or cells from Treg-recipient mice versus control mice within each cluster. Expression of genes from the (BF) 5 largest clusters are shown.
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Figure S3.6: Upregulated gene lists in GSEA analysis. The gene cluster 0 gene set from our single-cell
RNA-sequencing data was compared to a gene matrix of 123 gene lists. 47 of those gene lists were
positively enriched in the cluster 0 gene set. The normalized enrichment score (NES) of each of those gene
sets is plotted against the nominal p-value (NOM.p.val), with the number of enriched genes plotted as dot
size and the false discovery rate q-rate.
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Figure S3.7: Illustrated model demonstrating key findings of this study. Figure created using
BioRender.
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Chapter 4: IFNg-producing g/d T cells accumulate in the fetal
brain following intrauterine inflammation
Of note, exact text in Chapter 4 and figures 4.1-4.10 have been published in the following
article: Lewis, E.L., Tulina, N., Anton, L., Brown, A.G., Porrett, P.M., & Elovitz, M.A.
(2021). IFNg-Producing g/d T cells Accumulate in the Fetal Brain Following Intrauterine
Inflammation. Frontiers in Immunology, 12:741518.
https://doi.org/10.3389/fimmu.2021.741518.

Introduction
Maternal inflammation is associated with fetal brain injury and long-term
neurodevelopmental impairment. Intrauterine immune activation – whether from
maternal autoinflammatory disease, infection, or microbial dysbiosis– contributes to
offspring neurologic diseases from schizophrenia to autism spectrum disorder (ASD)
(Anders & Kinney, 2015; Easson & Woodbury-Smith, 2014; Lammert et al., 2018;
Madhusudan et al., 2012; Minakova & Warner, 2018). Overt symptoms of intrauterine
inflammation, or clinical chorioamnionitis, occur in a small number of deliveries and
likely do not identify the majority of infants at risk from exposure to intrauterine
inflammation (Conti et al., 2015). In contrast, histological chorioamnionitis (HCA),
postpartum pathologic evidence of intrauterine inflammation, occurs in 10-20% of term
deliveries with an increasing prevalence observed with decreasing gestational age
(Cappelletti et al., 2020; Conti et al., 2015; Lee et al., 2011). However, histologic
examination of postpartum tissue cannot explain how inflammation at the maternal-fetal
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interface initiates long-lasting injury in an entirely distinct anatomic compartment, the
fetal brain.
Immune activation in the central nervous system is posited to be a necessary
mechanistic link between a prenatal immune insult and select neurological disorders
(Anders & Kinney, 2015). Patients with schizophrenia have more activated microglia as
measured by PET uptake and more dense microglia in post-mortem studies (Bloomfield
et al., 2015; Kesteren et al., 2017). Patients with ASD have greater T cell infiltration at
the blood brain barrier in post-mortem studies (DiStasio et al., 2019). These two distant
immunologic findings – in utero and post-mortem – outline the wide knowledge gap in
the actual pathogenesis of these disorders. More mechanistic evidence exists for immune
cell development and the “immune education” that occurs prenatally, demonstrating that
immunologic memory begins in utero and influences immune cell responsiveness to
allergens, pathogens, and other antigens later in life (Mandal et al., 2013; Renz et al.,
2011). Neuroimmune “education” may also occur prenatally; for example, one mouse
model of ASD is initiated by injections of IL-17A to the fetal brain (Choi et al., 2016).
However, this model does not address how subclinical intrauterine inflammation could be
transmitted across the maternal-fetal dyad and induce fetal brain injury.
Our laboratory has established a mouse model of low-dose intrauterine inflammation
(IUI) that leads to fetal neuronal damage, including abnormal neuronal morphology and
decreased dendritic counts in cortical culture (Burd et al., 2010, 2011; Elovitz et al.,
2011). In this model, exposure to IUI induces transcriptional and metabolic alterations to
both fetal and neonatal brains, and a reduction in early postnatal neurogenesis (Brown et
al., 2017; Elovitz et al., 2011; Hester et al., 2018). This model of IUI also causes
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postnatal white matter damage and behavior abnormalities in adult offspring (Makinson
et al., 2017). These findings demonstrate the utility of this model for studying IUI as a
cause of fetal brain injury with long-term consequences. However, the mechanisms by
which IUI translate to neuronal damage have not been fully explored.
Therefore, the objective of this study is to identify the cellular immunologic changes
that propagate across anatomic compartments from the uterus to the fetal brain. Immune
cell populations and their responses are tissue-specific and must be analyzed as such.
Using an established mouse model of IUI, immune cell composition and function were
investigated by flow cytometry and ELISA over multiple prenatal time points in both
maternal and fetal murine tissues, and human cord blood. We hypothesize that IUI will
induce a cascade of cellular immune alterations, ultimately causing abnormal immune
cell trafficking and activation within the fetal brain itself.
Results
Intrauterine inflammation alters local, but not systemic, immune populations.
Our previous work utilizing our model of intrauterine inflammation (IUI) has
demonstrated minimal maternal immune activation after IUI, specifically noted by a lack
of maternal serum cytokine elevation (Elovitz et al., 2011). To confirm the hypothesis
that the maternal systemic immune system is not impacted by IUI, we compared maternal
splenic immune populations by flow cytometry (gating scheme in Figure S4.1) from mice
with IUI compared to saline-treated controls. From each spleen sample, 106 events were
run on the flow cytometer, leading to the acquisition of approximately 5x105 CD45+ cells
(Figure S4.2A). At both 48- and 72-hours post-uterine injection, none of the following
immune populations examined were significantly different between the two groups:
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macrophages, CD4+ T cells, CD8+ T cells, regulatory T cells, g/d T cells, B cells, NK
cells, neutrophils, and dendritic cells (Figures S4.2B-J).
Decidua, the specialized uterine lining that develops during pregnancy, was collected
from these same mice to examine immune changes local to the uterus at 48- and 72-hours
post-uterine injection. The presence of IUI increased numbers of CD45+ cells in decidual
tissue (Figures 4.1A,D), primarily due to an influx of decidual neutrophils (Figures 4.1BC,E). This neutrophil influx was evident as both an increase in absolute number of
decidual neutrophils (Figure 4.1B) and an increase in neutrophil frequency of decidual
leukocytes (Figure 4.1C). The decidual neutrophil increase persisted in the mice with IUI
at 72 hours post-uterine injection (Figures 4.1B-C) and these mice also had a slight
elevation in decidual CD8+ T cells at 72 hours post-uterine injection (Figures 4.1F). The
two most prevalent decidual immune cells, NK cells and macrophages (Erlebacher, 2013;
Yang et al., 2019) did not differ between the IUI and control groups (Figures 4.1G-H).
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Figure 4.1: Intrauterine inflammation causes sustained influx of neutrophils to the decidua.
Decidua was removed from the uterus at 48 and 72 hours post-uterine injection. All decidual cells were
analyzed by flow cytometry to have full counts of (A) CD45+ cells. (D) Representative flow plots of total
CD45+ cells are gated on non-debris, singlet, live cells. Immune cell subsets were reported both as cell
counts and as a percent of total CD45+ cells, including (B-C) neutrophils, (F) CD8+ T cells, (G) NK cells,
and (H) macrophages. (E) Representative flow plots of neutrophils were gated on non-debris, singlet, live,
CD45+, CD19-, CD4- , CD8- cells. Significance was determined by unpaired t-test with Welch’s correction
if positive F-test. *:p<0.05, **:p<0.01, ****:p<0.0001.

Placentae and amniotic fluid have elevated leukocyte counts and chemokine levels
following intrauterine inflammation.
To test the hypothesis that IUI would alter immune responses both within and across
the placenta, flow cytometry was used to identify immune cells in the placentae and
amniotic fluid of mice with IUI and controls. At 48 hours post-uterine injection, both the
placentae and amniotic fluid of mice exposed to IUI had more total leukocytes than
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controls, but these levels normalized by 72 hours post-exposure (Figures 4.2A-D).
Neutrophil increases in both the placenta and amniotic fluid accounted for most of the
leukocyte increase in mice with IUI at 48 hours post-uterine injection and neutrophil
counts in the placentae and amniotic fluid of mice with IUI also had normalized by 72
hours post-uterine injection (Figures 4.2E-F). Placentae, but not amniotic fluid, from
mice with IUI had a small increase in macrophages (Figures 4.2G-H), but no other
immune cell differences from control animals were observed by 72 hours post-uterine
injection.
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Figure 4.2: Intrauterine inflammation increases leukocytes found in the placenta and amniotic
fluid. Placentae adjacent to the injection site and total amniotic fluid were collected at 48 and 72 hours
post-uterine injection and immune cells were analyzed by flow cytometry. Representative flow plots of
CD45+ cells in the (A) placenta and (B) amniotic fluid were gated on non-debris, singlet, live cells. (C, D)
CD45+ cells, (E, F) neutrophils, and (G,H) macrophages were counted at each time point. Cell counts were
tested for normal distribution by Shapiro-Wilk test. Normally distributed data was then analyzed by
unpaired t-test and non-normally distributed data was analyzed by Mann-Whitney test. *:p<0.05, ***:p<0.
001.

Given the increase in CD45+ cells in the placentae and amniotic fluid of mice with IUI,
we asked whether this was accompanied by an increase in chemokines that may recruit
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CD45+ cells to these tissues. Our previous work with this model of IUI had demonstrated
significant elevations in CCL3, CCL5, and IL-6 in both the placenta and amniotic fluid at
just 6 hours post-exposure (Burd et al., 2011; Elovitz et al., 2011; Tulina et al., 2018), so
we investigated whether these chemokines remained elevated at later time points. CCL5
was the most increased: 31-fold in the placenta and 8-fold in the amniotic fluid of mice
with IUI at 48 hours post-uterine injection; but protein levels of this chemokine
normalized to control levels by 72 hours post-uterine injection (Figures 4.3B, E). CCL3
was also elevated in the placenta and amniotic fluid in mice with IUI at 48 hours and
normalized by 72 hours post-uterine injection (Figures 4.3A, D). IL-6 was elevated in the
placenta but not the amniotic fluid of mice with IUI at 48 hours and was not significantly
increased in either tissue at 72-hours post-injection (Figures 4.3C, F).

Figure 4.3: Elevated chemokines found in the placenta and amniotic fluid following intrauterine
inflammation. Cytokines were measured in the placenta and amniotic fluid by ELISA, from samples
collected at 48 and 72 hours post-uterine injection. (A-C) Placental ELISA values were normalized to total

86

placental protein measured by BCA, while (D-E) amniotic fluid ELISA values were normalized to fluid
volume. Significant differences were determined by two-way ANOVA followed by post-hoc Tukey’s
multiple comparison test. *:p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001.

Exposure to intrauterine inflammation alters immune populations in the fetal liver.
Given that immune alterations were detected in the amniotic fluid of IUI-exposed mice,
we hypothesized that the fetal immune system would be perturbed. In the fetal livers of
mice exposed to IUI, CCL3 and IFNg were elevated at 48 hours post-uterine injection and
had normalized by 72 hours (Figures 4.4A, C). There was no significant difference in
CCL5 levels between IUI-exposed and control fetuses (Figure 4.4B). No cellular immune
changes were noted at 48 hours in the fetal liver. However, following the observed
cytokine elevation at 48 hours, at 72 hours post-uterine injection, fetuses exposed to IUI
had more CD45+ cells, neutrophils, and macrophages (Figures 4.4D-I) than control
fetuses in their fetal livers.
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Figure 4.4: Neutrophil and cytokine elevation in the fetal liver demonstrate systemic fetal
inflammation. Fetal livers were collected at 48 and 72 hours post-uterine injection and either frozen or
processed for flow cytometry. (A-C) Frozen fetal livers were tested for cytokines by ELISA and
normalized to total protein. Fresh fetal livers were analyzed by flow cytometry for immune cells. (D-E)
Total CD45+ cells, (F-G) neutrophil, and (H-I) macrophage cell counts are shown. (D) Representative flow
plots of CD45+ cells were gated on non-debris, singlet, live cells. (F) Representative flow plots of
neutrophils were gated on non-debris, singlet, live, CD45+, CD3-, CD19- cells. (H) Representative flow
plots of macrophages were gated on non-debris, singlet, live, CD45+, CD3-, CD19- cells. Cell count data
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was analyzed by Mann-Whitney test. Cytokine data were analyzed by two-way ANOVA with post-hoc
Tukey’s multiple comparison test. *: p<0.05, **:p<0.01.

Activated microglia and granulocytes are increased in fetal brains from in fetuses
exposed to intrauterine inflammation.
To address whether an inflammatory insult in the uterus could ultimately alter immune
cell composition and function in the fetal brain, we isolated mononuclear cells from fetal
brains and identified the immune cell types by flow cytometry (gating scheme in Figure
4.5A). At 48 hours post-uterine injection, the only detectable difference in the fetal brain
immune cells was a 5-fold increase in granulocytes in the IUI-exposed group (Figure
4.5F). However, by 72 hours post-uterine injection, fetal brains from IUI-exposed dams
had more overall CD45+ cells (Figure 4.5B) and specifically non-microglial CD45+ cells
(Figure 4.5E), including 7-fold more granulocytes (Figure 4.5F). IUI-exposure increased
the numbers of activated microglia and macrophages but did not affect the numbers of
resting microglia (Figure 4.5C-D,G).
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Figure 4.5: Intrauterine inflammation results in fetal microglial activation and an increase in nonmicroglial immune cells in the fetal brain. Fetal brains were collected at 48 and 72 hours post-uterine
injection and processed for flow cytometry. (A) The gating scheme used to identify immune cells in the
fetal brain is shown. (B) Total CD45+ cells and immune cell subtypes were counted. Subtypes include: (C)
resting microglia, (D) activated microglia, (E) all non-microglia CD45+ cells, (F) granulocytes, and (G)
monocytes/macrophages. All cell count data was analyzed by Shapiro-Wilk test to establish data
distribution. Normally distributed data were analyzed by unpaired t-test and non-normally distributed data
were analyzed by Mann-Whitney test. *: p<0.05, **:p<0.01, ***:p<0.001.
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Unbiased analyses identify Gr-1+ g/d T cells as highly increased in the IUI-exposed fetal
brains.
Given limited studies on what immune cells can be found in the fetal brain, we relied
on unbiased clustering algorithms to determine the immune population with the greatest
difference between fetal brains from IUI-exposed and control dams. tSNE analysis
creates a visual map of the different CD45+ cells found in the fetal brain, with a clear
population enriched in the brains of fetuses exposed to IUI (black box, Figure 4.6A). The
flowSOM algorithm generated ten different clusters of immune cells in the fetal brain
(different colored clusters in Figure 4.6A). The absolute difference between the
frequency of each flowSOM cluster in the fetal brains of IUI-exposed versus control mice
was calculated and the population with the greatest difference was identified (purple
population, Figures 4.6A-B). This population accounted for 7% of all CD45+ cells in the
brains from IUI-exposed fetuses, but less than 1% of CD45+ cells in brains of control
fetuses. This immune cell population was Gr-1+ CD11b+ g/d T cells (histograms in
Figure 4.6B). Total g/d T cells were elevated in the fetal brains from IUI-exposed dams at
both 48 and 72 hours post-uterine injection (Figures 4.6C-D). Total g/d T cells were also
increased in the decidua of IUI-exposed dams at 72 hours post-uterine injection (Figure
S4.3A), but were not changed in the spleen (Figure S4.2F), placenta, amniotic fluid, or
fetal liver by IUI (Figures S4.3B-D).
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Figure 4.6: Intrauterine inflammation increases g/d T cells in the fetal brain. Fetal brains were
collected at 48 and 72 hours post-uterine injection and processed for flow cytometry. CD45+ cells in the
fetal brain at 72 hours were analyzed by FlowJo plug-ins tSNE and flowSOM to visualize and identify
clusters, respectively. (A) Fetal brain CD45+ cells from saline-control and IUI-exposed dams were
visualized by tSNE and colored by flowSOM populations. Black box indicates the most increased
population by IUI. (B) Histograms of marker expression for two populations identified by flowSOM: the
largest population (blue) and the population most increased by IUI-exposure (purple). (C) Representative
flow plots of the g/d T cells in the fetal brain, gated on non-debris, singlet, live, CD45+, non-microglia,
CD19- cells. (D) g/d T cells were counted in each fetal brain sample. All cell count data was analyzed by
Shapiro-Wilk test to establish data distribution. Normally distributed data were analyzed by unpaired t-test
and non-normally distributed data were analyzed by Mann-Whitney test. Normally distributed data with
positive F-test for unequal variance were analyzed by unpaired t-test with Welch’s correction. *: p<0.05.

g/d T cells in the fetal brain, but not the decidua or maternal spleen, produce IFNg
following intrauterine inflammation.
To elucidate the function of the g/d T cells in the IUI-exposed fetal brains, T cells were
isolated from pregnant mice 72-hours after exposure to IUI from the maternal spleen,
decidua, and fetal brain. T cells were stimulated in vitro for four hours and for
intracellular cytokines. Cells were also stained for TCRb and TCRgd to differentiate
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between a/b and g/d T cells. Cytokine production by g/d T cells varied immensely by
anatomic location (Figures 4.7A-D). Less than 10% of all splenic T cells were producing
measurable cytokines, 30% of decidual T cells were producing TNFa, and nearly 100%
of T cells in the fetal brain were producing at least one cytokine (Figures 4.7A-B). About
20% g/d T cells from the fetal brain produced IL-17A or TNFa, while 85% of fetal brain
g/d T cells produced IFNg (Figure 4.7B). Whether examining total T cells or only g/d T
cells, only those isolated from the fetal brain were making significant IFNg (Figures
4.7C-D).

Figure 4.7: g/d T cells from the fetal brain, but not from the maternal spleen or decidua, are
producing IFNƔ. CD3+ cells were isolated from tissues collected at 72 hours post-exposure to IUI. CD3+
cells were stimulated in vitro and stained for intracellular cytokines. (A) Representative flow plots from the
decidua and fetal brain are gated on non-debris, singlet, live, CD45+, CD3+ cells. Cytokine expression was
analyzed as (B) the % of T cells that were positive for each cytokine and as the MFI of either (C) total
CD3+ cells or (D) CD3+ TCRg/d+ cells. Cytokine data was analyzed by two-way ANOVA with post-hoc
Tukey’s multiple comparison test. *: p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001.
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IFNg is elevated in umbilical cord blood from term neonates with histological
chorioamnionitis.
Term HCA was used as a human correlate to our mouse model of low dose intrauterine
inflammation without preterm birth, as HCA is defined by placental neutrophil infiltrates
(Cappelletti et al., 2020). Cord blood was collected from term pregnancies (delivery at
greater than 37 weeks) and placentae from these pregnancies were examined for
histological chorioamnionitis (HCA) as part of clinical care. A case control study was
performed. Cases were defined by the finding of HCA on placental pathology (N=36)
compared to controls who did not have HCA (N=41). Cases and controls were frequency
matched by self-reported race (Table 4.1). IFNg and TNFa were measured in cord blood
by a high-sensitivity Luminex assay. IFNg levels were 1.8-fold higher in cord blood from
neonates with HCA compared to controls (p<0.0001), but TNFa was equivalent between
cases and controls (Figures 4.8A, B), indicating an IFNg specific inflammatory signature
in neonates with HCA. Fetal sex did not contribute to cytokine level variance.

Figure 4.8: Cord blood from neonates with histological chorioamnionitis have elevated IFNg.
Cytokine levels were measured in a matched case-control study of cord blood plasma from term neonates
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(>37 weeks gestational age at delivery) with and without histological chorioamnionitis (HCA). (A) IFNg
and (B) TNFa were measured by Milliplex assay in 41 cases with HCA and 36 controls. Neonatal sex is
noted by symbol shape: squares are male and circles are female. Sex did not impact variance in cytokine
levels as measured by two-way ANOVA. Differences in cytokine levels were analyzed by Mann-Whitney
test. ****:p<0.0001.
Table 4.1: Demographic table of study participants.

Discussion
The developing brain is exquisitely sensitive to intrauterine inflammation (IUI) such
that the inflammatory insult may be asymptomatic in the mother but may cause longlasting neuronal damage in the fetus. This study identifies a cascade of immunological
events across the maternal-fetal dyad, demonstrating an active local immune response in
the absence of systemic inflammation. The immune response in each compartment
differed in cellular content, cytokine activation, and reaction time, emphasizing the
importance of tissue-specific immunity and validating the necessity to examine each
compartment across the maternal-fetal dyad. Activated IFNg+ Gr-1+ g/d T cells in the
fetal brain are a novel population that may be essential for fetal brain injury and IFNg95

driven inflammation may be critical for both identifying neonates at risk of brain injury
and understanding the specific pathogenesis of neuroimmune diseases from exposure to
prenatal inflammation.
The mouse model used in this study recapitulates the clinical phenotype as: exposed
dams exhibit no sign of systemic illness or immunologic shifts. Yet, even in the absence
of systemic immunological shifts, significant immune responses occur at the maternalfetal interface and within the fetus. This model greatly differs from other models of
maternal inflammation inducing fetal brain damage, in which polyI:C (Choi et al., 2016;
Cui et al., 2020; Lammert et al., 2018), LPS (Prins et al., 2015), IL-1b (Leitner et al.,
2014; Novak et al., 2019), or pathogen-specific antigens (Z. Xu et al., 2021) are injected
systemically into the mother to mimic a viral-like illness (Lutz et al., 2021; Smolders et
al., 2018). Overt maternal illness occurs in only a minority of cases of IUI as indicated by
histological chorioamnionitis (Cappelletti et al., 2020; Lee et al., 2011); as such, the
model utilized in these studies, more accurately recapitulates mechanism of disease in
human pregnancy. Most cases of human IUI are thought to be caused by ascension of
vaginal bacteria to the uterus (Cappelletti et al., 2020). Maternal intestinal microbiota
also influences the development of ASD in offspring, whereby the microbiota affects
maternal immune and metabolic factors that reach the fetus and change fetal
neurodevelopment (Jašarević & Bale, 2019; S. Kim et al., 2017; Lammert et al., 2018;
Minakova & Warner, 2018). Our model better mimics the subtle local inflammatory
changes initiated by microbial products or microbial ascension to the uterus when
compared to systemic inflammatory models.
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Despite the different modes of inducing inflammation, our model demonstrates a
neutrophil influx to the decidua, placenta, and amniotic fluid – which is consistent with
other animal and human studies (Edey et al., 2016; Gomez-Lopez et al., 2018; Lutz et al.,
2021; Presicce et al., 2018, 2020). Neutrophil infiltrates to the placenta are also
diagnostic of human histological chorioamnionitis (Cappelletti et al., 2020). The local
immune response at the maternal-fetal interface therefore appears similar whether the
inflammatory insult is local or systemic. Importantly, this study demonstrates that a lack
of maternal systemic immune activity does not reflect the immune activity of the
maternal-fetal interface.
The duration of our study gives more context to the local immune cell infiltrates
associated with IUI (Figure 4.9). Neutrophils are increased in the placenta and amniotic
fluid at 48 hours post-uterine injection but have returned to control numbers by 72 hours.
We find a similar trend with inflammatory cytokines in the placenta and amniotic fluid.
Previous data from our laboratory has shown massive increases in IL-6 in the placenta
and amniotic fluid in IUI-exposed pregnant mice at 6 hours post-uterine injection (Brown
et al., 2019; Elovitz et al., 2011). These current data show increases in CCL3, CCL5, and
IL-6 in IUI-exposed pregnant mice at 48 hours, but by 72 hours post-uterine injection,
these cytokines are returning to control levels. These data demonstrate a wave of
inflammation through the placenta and amniotic fluid that is subsiding by 72-hours after
initial insult.
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Figure 4.9: Temporal dynamics of immune infiltrates differed in each anatomic compartment. IUIexposed mice had more CD45+ cells compared to controls in each examined tissue, but at different times
post-uterine injection and with different immune subtypes. This figure demonstrates: the lasting neutrophil
infiltrate in the decidua (purple) at 48 and 72 hours post-uterine injection; the neutrophil infiltrate to the
placenta (pink) at 48 hours that normalizes to control levels by 72 hours; the increase in macrophages and
neutrophils to the fetal liver (green) at 72 hours; and the increase in g/d T cells and activated microglia in
the fetal brain (yellow) at 72 hours post-uterine injection. Figure created using BioRender.

Even as inflammation in the placenta and amniotic fluid is lessening by 72-hours postuterine injection, cellular changes to the fetal immune system in IUI-exposed fetuses are
just becoming apparent (Figure 4.9). The increase in macrophages and neutrophils in the
fetal livers of IUI-exposed fetuses is a novel finding that indicates IUI not only may
affect neurodevelopment but also immune system development. These findings are
consistent with the immune irregularities and increased autoimmunity that are present in
patients with ASD (Anders & Kinney, 2015; Meltzer & Water, 2016). Fetal immune
activation in our mouse model may be a direct response to LPS, as LPS is able to cross
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the placenta into fetal tissue and fetal TLR4 activation is necessary for LPS-induced brain
damage (Brown et al., 2019; Tulina et al., 2018). Prenatal exposures to microbial
products impact allergic sensitivity and tolerance induction of fetal immune cells of both
mice and humans (Ege et al., 2008; Mincham et al., 2018). Fetal blood brain barrier
permeability is influenced by maternal microbiota and immune activity (Braniste et al.,
2014; Cui et al., 2020). Fetal inflammation following maternal immune activation leads
to an accumulation of immune cells at the embryonic choroid plexus and a weakening of
tight junctions at the blood brain barrier (Cui et al., 2020). This weakened barrier likely
allows for the increased infiltration of non-microglial CD45+ cells that we find in the
brains of IUI-exposed fetuses (Figure 4.5E) and provides a model for our findings (Figure
4.10).

Figure 4.10: Model figure of the mechanism of fetal brain injury in the setting of intrauterine
inflammation. This model demonstrates how g/d T cells in the fetal brain may lead to fetal brain injury.

99

This model reflects both data in this paper and data from previously published literature that demonstrate
that (1) the fetal blood brain barrier is weakened by maternal inflammation, (2) during systemic
inflammation g/d T cells may traffic to the brain, (3) an increase in IFNg+ g/d T cells are present in the fetal
brain following IUI, (4) IFNg leads to microglial activation, and (5) prenatal microglial activation can cause
neuronal injury. Figure created using BioRender.

The detection of increased IFNg in mouse fetal livers of IUI-exposed fetuses and in
human cord blood supports a more systemic immune activation occurring in the fetus in
response to IUI. This systemic fetal inflammation may specifically initiate g/d T cell
trafficking to the brain, as has been reported to occur neonatal sepsis (X. Zhang et al.,
2017). Similarly, in experimental autoimmune encephalomyelitis, g/d T cells are thought
to be primed in the periphery and then travel to the central nervous system (CNS), where
they are able to augment CNS pathology (Malik et al., 2016). Consistent with reports that
demonstrate peripheral g/d T cells traffic to the brain (Benakis et al., 2016; Malik et al.,
2016; X. Zhang et al., 2017), in the fetus g/d T cells are found in the skin, intestines and
meninges (Ribot et al., 2021). Recent work has demonstrated that the presence of
meningeal g/d T cells in neonates are critical for short-term memory and synaptic
plasticity (Ribeiro et al., 2019). Interestingly, these physiologic g/d T cells produce IL-17
(Ribeiro et al., 2019), while the g/d T cells that we detected in the fetal brain produce
IFNg, suggesting a different, possibly pathologic, activation state.
As the bidirectional crossing of immune cells between mother and fetus remains a
poorly studied area (Kinder et al., 2017), one might argue that the g/d T cells may be
maternal in origin. Based on prior data showing very few maternal-derived cells in the
fetal liver (Lewis et al., 2018), we suggest that the fetal brain g/d T cells are likely fetal in
origin. Furthermore, the earliest fetal g/d T cell progenitors to exit the thymus at E13
100

express IFNg (Ribot et al., 2021), which is consistent with the phenotype of the g/d T
cells in this study.
The expression of both Gr-1 and CD11b on the g/d T cells in this study is consistent
with their IFNg production. Gr-1 has been used as a marker of IFNg-producing rather
than IL-17-producing g/d T cells in the setting of bacterial pneumonia (Wanke‐Jellinek et
al., 2016), and CD11b+ g/d T cells are reported to produce IFNg and to present
exogenous antigens (Lebedev et al., 2021). Together the phenotype of these g/d T cells
suggests they are responding to and exacerbating fetal inflammation in this model. The
production of IFNg by g/d T cells in the fetal brain may is one plausible mechanism by
which these g/d T cells cause brain injury, as microglial exposure to IFNg initiates a
microglial activation state that is pro-inflammatory and neurotoxic (Papageorgiou et al.,
2016; Ta et al., 2019). Microglia impacted by inflammation in the “pre-microglial” phase
from E14 to one month of life are particularly sensitive to inflammation and rearrange
their chromatin landscape to create lasting changes in gene expression patterns (Cao et
al., 2015; Matcovitch-Natan et al., 2016). These early epigenetic changes to microglia
may explain the long-term neurobehavioral outcomes from prenatal exposure to
inflammation.
While the initial injury may be prenatal, neuroimmune pathologies may be treated
postnatally. In multiple animal models of prenatal neuronal injury and inflammation,
postnatal treatments have reversed neurologic, immunologic, and even behavior
abnormalities in the exposed offspring (John et al., 2017; Wixey et al., 2019; Z. Xu et al.,
2021; Yellowhair et al., 2019). The potential for treatment heightens the necessity for
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early diagnosis. Given the absence of a systemic maternal signal for the presence of
intrauterine inflammation, other avenues to identify fetuses and neonates at risk are
mandated. Assessing the immunological state of a neonate is feasible with testing of the
cord blood immediately following delivery. Our finding of increased IFNg in human cord
blood from neonates with HCA demonstrates the plausibility of cord blood containing an
immune signature of neuronal injury. The increased cord blood IFNg indicates that
inflammation from HCA is not isolated to the placenta and impacts the fetus itself.
Additionally, the elevation of IFNg but not TNFa suggests an adaptive over innate fetal
response to HCA.
One limitation to this study is that T cell development in the mouse occurs later in
gestation than in humans. In mice, g/d T cells do not develop until E13 and a/b T cells
mostly mature postnatally, whereas human T cell development begins at week 11-12 of
pregnancy (Khairallah et al., 2018; J.-E. Park et al., 2020). Therefore, the fetal immune
response observed in the mouse may not be wholly reflective of that in a human fetus.
However, postmortem studies from human preterm infants have shown g/d T cells in
neonatal brains with injury (specifically periventricular leukomalacia) but not in preterm
infants without brain injury (Albertsson et al., 2017), indicating that g/d T cells may be
critical to fetal brain injury regardless of the presence of a/b T cells. g/d T cells were also
found in a sheep model of fetal asphyxia-induced brain injury (Albertsson et al., 2017),
suggesting a conserved role for g/d T cell in prenatal neuropathology, regardless of the
initial insult. In addition, in multiple mouse models of neonatal brain injury (sepsis,
hypoxia-ischemia), g/d T cells were required to cause brain injury, and depletion of g/d T
102

cells was protective (Albertsson et al., 2017; X. Zhang et al., 2017). g/d T cells are also
implicated in multiple ‘adult’ neuroinflammatory diseases including encephalitis,
multiple sclerosis, and ischemic stroke (Albayrak, 2016; Benakis et al., 2016;
Gelderblom et al., 2014; Malik et al., 2016). These findings suggest a specific role for g/d
T cells, rather than a/b T cells, in neuroimmune disease.
Overall, our data support a model of fetal brain injury where local intrauterine
inflammation progresses to systemic fetal inflammation, which then creates the
conditions for activated g/d T cells to cross the blood brain barrier, make IFNg, and
activate fetal microglia (Figure 4.10). The lack of maternal systemic inflammation posits
a challenge for prenatal diagnosis of neurodevelopmental disorders. However, detection
of IFNg in human cord blood provides the potential for early neonatal diagnosis, and thus
treatment, of prenatal neuronal damage. These findings demonstrate a complex immune
response in the maternal-fetal dyad that participate in fetal brain injury from exposure to
prenatal inflammation. Importantly, this work identifies a potential target and/or marker
of fetal brain inflammation through the identification of g/d T cells in our mouse model
and elevated IFNg in term HCA. Being able to identify, through cord blood biomarkers,
neonates at greatest risk for neuroimmune activation, may provide a novel opportunity
for pharmacologic interventions to prevent adverse neurobehavioral outcomes associated
with prenatal inflammation.
Methodology
Study Design: The goals of this study were to elucidate immune compositional and
functional shifts associated with fetal brain injury in a mouse model and to correlate our
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findings to human cord blood samples. Flow cytometry and ELISA data are each
compiled from a minimum of two experiments per time point with our mouse model and
an N=4-6 mice/group/experiment. Human cord blood was obtained from an existing
biorepository of cord blood serum collected for detection of biomarkers of fetal
pathologies.
Animals: These studies utilize a well-established mouse model of intrauterine
inflammation created by our lab and resulting in fetal and postnatal brain injury (Burd et
al., 2011; Elovitz et al., 2011). For these experiments, timed-pregnant CD-1 mice were
purchased from Charles River Laboratories (Wilmington, MA) and arrived at our animal
facility at embryonic day 11 (E11). On E15, pregnant mice underwent a mini-laparotomy,
while under isoflurane anesthesia. Each mouse received an injection into their right
uterine horn, between the first and second amniotic sacs proximal to the cervix, as
previously described (Burd et al., 2009; Elovitz et al., 2003, 2006). Each injection was
either 100µl sterile phosphate buffered saline (PBS; saline control group) or 50µg/100µl
lipopolysaccharide (LPS)/sterile PBS (IUI-exposed group). LPS was from E. coli 055:B5
(Sigma, St. Louis, MO). Mice were then euthanized by CO2 either 48 or 72 hours postIUI, with tissues collected only from mice that were still pregnant. All animal care and
use procedures are approved by the University of Pennsylvania IACUC.
Tissue Collection: At either 48 or 72 hours post-IUI, mice were euthanized and tissues
were collected into and washed with 10% charcoal-stripped fetal bovine serum (FBS;
Gemini Bio, Sacramento, CA) in Hank’s balanced salt solution (HBSS) on ice. Maternal
spleen was collected. Amniotic fluid was removed from each gestational sac with a 1ml
syringe. The uterus was bisected and gestational sacs with fetal membranes and placentae
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were removed. The decidua was then scraped from uterus with a glass microscope slide
into HBSS + 10% FBS on ice. Fetal tissues, placentae, fetal liver and fetal brains, were
collected from the four fetuses proximal to the injection site and washed in HBSS + 10%
FBS on ice. Tissues were either flash frozen in liquid nitrogen and stored at -80°C or
immediately processed into a single cell suspension for flow cytometry.
Single Cell Suspension: Preparation of tissues for flow cytometry follows a protocol
established with the placenta (Lewis et al., 2018). Placentae were minced into 2mm
pieces, suspended in 5ml of digest solution (HBSS + 10% FBS + 1mg/ml Collagenase
IV, Gibco, Gaithersburg, MD), and incubated in a 37°C water bath for 30 minutes.
Placentae (post-digest treatment), maternal spleens, decidua, fetal livers, and fetal brains
were mechanically pressed through a 70µm cell strainer. The strainer was rinsed with
10ml of HBSS and strained cells were passed through a 40µm cell strainer into a 50ml
conical tube. Cells were centrifuged at 1500rpm, 4°C for 10 minutes. Red blood cells
were eliminated from placentae, maternal spleens, decidua, and fetal livers by suspension
in 3ml of ACK lysing buffer (Gibco, Gaithersburg, MD) and incubation at room
temperature for 10 minutes. ACK-treated cells and amniotic fluid samples were rinsed in
10ml of HBSS and centrifuged at 1500rpm, 4°C for 5 minutes. Single cell suspensions
from maternal spleen, decidua, placentae, fetal livers, and amniotic fluid were suspended
in 1ml of FACS buffer (PBS + 2% FBS + 20µM EDTA) and transferred into 5ml roundbottom tubes through 35µm filter caps. Cells were stored on ice until ready for staining.
Isolation of Mononuclear Cells from Fetal Brains: Fetal brain single cell suspension
was suspended in 5ml 35% Percoll and was slowly layered on top of 5ml 70% Percoll in
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a 15ml conical tube. Cells in Percoll gradient were centrifuged at 1000xg, 4°C, for 20
minutes without centrifuge break. Myelin and glial cells were removed from the top of
the gradient and then 1ml at the interface was collected, containing mononuclear cells.
Mononuclear cells were washed in 10ml HBSS and centrifuged at 1500rpm, 4°C for 10
minutes. Cells were resuspended in 1ml FACS buffer and transferred into 5ml roundbottom tubes through 35µm filter caps.
Cell Staining for Flow Cytometry: Cells were transferred to a 96-well round-bottom
plate for staining, washed with 200µl of PBS, and the plate was centrifuged at 1500rpm,
4°C for 5 minutes. Cells were resuspended in 100µl of Live/Dead Fixable Aqua
(Invitrogen, Waltham, MA) diluted 1:1000 in PBS and incubated for 30 minutes at 4°C in
the dark. Cells were washed twice with 200µl of FACS buffer, centrifuging the plate
between washes at 1500rpm, 4°C for 5 minutes. Cells were then resuspended in an
extracellular antibody mix and incubated for 30 minutes at 4°C in the dark. Extracellular
antibody mixes included: anti-CD3e-BV785, anti-CD4-BV605, anti-CD11c-PE.Cy7,
anti-CD19-APC, anti-CD45-BV711, anti-CD49b-PacificBlue, anti-CD80-PacificBlue,
anti-F4/80-FITC, anti-Ly6G-AF700, anti-TCRg/d-PerCP.Cy5.5 (BioLegend, San Diego,
CA); anti-CD8a-APC.efluor780, and anti-Gr1-AF700 (eBioscience, San Diego, CA).
Cells were washed twice with 200µl of FACS buffer, centrifuging between washes at
1500rpm, 4°C for 5 minutes. Cells were resuspended in 200µl fixation/permeabilization
reagent (Transcription Factor Staining Buffer Set, eBioscience, San Diego, CA) and
incubated for 30 minutes at 4°C in the dark. Cells were washed twice with 200µl of
permeabilization buffer (Transcription Factor Staining Buffer Set, eBioscience, San
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Diego, CA), centrifuging at 2000rpm, 4°C for 5 minutes between washes. Cells were
resuspended in anti-FoxP3-PE (eBioscience, San Diego, CA) diluted 1:300 in 100µl
permeabilization buffer and incubated for 30 minutes at room temperature in the dark.
Cells were washed twice with 200µl of permeabilization buffer, centrifuging at 2000rpm,
4°C for 5 minutes between washes. Cells were then resuspended in 200µl of FACS buffer
and transferred into 5ml round-bottom tubes through 35µm filter caps and stored at 4°C
in dark. Single-stained CompBeads (BD Biosciences, Franklin Lakes, NJ) were used as
compensation controls to create a compensation matrix, and fluorescence minus onestained splenocytes and placental cells (FMOs) were used as gating controls to draw
gates. See gating scheme (Figure S4.1). All samples were analyzed by an LSR-II flow
cytometer (BD Biosciences, Franklin Lakes, NJ).
Cytokine ELISAs: Tissues to be used for ELISA were flash frozen in liquid nitrogen at
the time of tissue harvest and were stored at -80°C. Amniotic fluid samples to be used for
ELISA were centrifuged at 3000rpm for 5 minutes and the supernatant was flash frozen
for future use. Protein extracts were made from placentae or fetal liver tissue by
submerging 50mg of frozen tissue in 1ml of RIPA buffer with cOmplete mini protease
inhibitor cocktail (Roche, Basel, Switzerland) in a 2ml round bottom tube with a 5mm
steel bead. Tissue was homogenized on Tissue Lyser II (Qiagen, Venlo, Netherlands) for
10 minutes at 30/second. Homogenate was rested on ice for 40 minutes and then
centrifuged at 14000xg for 10 minutes. Total protein in supernatant was quantified by the
BCA protein assay kit (Pierce, Rockford, IL) following the manufacturer’s protocol.
Quantikine ELISA kits (R&D Systems, Minneapolis, MN) for IL-6, IL-10, IFNg, CCL3,
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and CCL5 were used to measure cytokine levels, following the manufacturer’s protocol.
Cytokine levels were normalized to total protein.
Intracellular Cytokine Staining: Fetal brains, decidua and maternal spleen were
collected 72 hours post-intrauterine injection of LPS and processed into a single cell
suspension as noted above. CD3+ cells were isolated from the single-cell suspension
using mouse CD3e microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany)
following the manufacturer’s protocol. Isolated CD3+ cells were resuspended at 106
cells/ml in T cell stimulation media: RPMI-1640 with L-glutamine (Corning Inc.,
Corning NY) supplemented with 50µM beta-mercaptoethanol (Sigma-Aldrich, St. Louis,
MO), 1X non-essential amino acids, 1X sodium pyruvate, 1X HEPES buffer (Gibco,
Gaithersburg, MD), 1X Cell Stimulation Cocktail, 1X Protein Transport Inhibitor
Cocktail (eBioscience, San Diego, CA), and 10% FBS. 100µl of each sample was plated
on a 96-well round-bottom plate and incubated for 4 hours at 37°C. Cells were
centrifuged at 400xg, 4°C, for 5 minutes, washed with PBS, resuspended in Live/Dead
Fixable Aqua 1:2000 in 100µl of PBS, and incubated for 30 minutes at 4°C. Cells were
then washed twice with FACS buffer; stained with extracellular markers, anti-CD45BV711, anti-CD3e-BV785, anti-TCRg/d -PerCP-Cy5.5, anti-TCRb-APC-Cy7
(BioLegend, San Diego, CA); and incubated for 30 minutes at 4°C. Cells were washed
twice with FACS buffer and resuspended in Fixation/Permeabilization reagent
(eBioscience, San Diego, CA) for 30 minutes at 4°C. Cells were washed twice with
Permeabilization Buffer and then incubated for 30 minutes at 4°C with intracellular
cytokine staining antibodies: anti-TNFa-FITC (BioLegend, Sand Diego, CA), anti-IFNg108

BV421, and anti-IL-17A-PE (BD Biosciences, San Jose, CA). Cells were washed twice
with Permeabilization Buffer and then resuspended in FACS buffer and stored at 4°C in
dark until run on flow cytometer.
Flow Cytometry Analysis: Cells were analyzed on an LSR-II flow cytometer (BD
Biosciences, San Jose, CA) running FACSDiva software (BD Biosciences, San Jose, CA)
in the University of Pennsylvania Flow Core. Flow cytometry data was then analyzed
using FlowJo (BD Life Sciences, Ashland, OR) to identify immune cell subsets. Highdimensional, unbiased cell clustering and visualization tools were used to further analyze
flow cytometry data. Specifically, t-SNE and FlowSOM algorithms were downloaded
from the FlowJo Exchange and implemented using R/Bioconductor (Gassen et al., 2015).
Case-Control Study: Cord blood was obtained from a previously published cohort of
singleton pregnancies (N=723) (Bastek et al., 2013; Elovitz et al., 2015) of which 77
specimens were utilized in this study. Case specimens were selected as term neonates
(>37 weeks gestational age at delivery) with documented HCA (N=41). Control
specimens were also from term neonates (>37 weeks) that had placental histological
examination but no HCA and were frequency matched for maternal race (N=36). All
participants provided informed consent and the study was approved by the Institutional
Review Board at the University of Pennsylvania (IRB #807678). Cord blood serum was
analyzed by high sensitivity Milliplex assay (Millipore Sigma, Burlington, MA) for IFNg
and TNFa.
Statistical Analysis: Statistical analyses were performed using GraphPad Prism. Data
for every analysis is compiled from at least two experiments with 4-6
samples/group/experiment. Flow cytometry data was analyzed for differences between
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IUI and control samples collected at the same time – not for differences over time. All
data was assessed for normality by Shapiro-Wilk test. Non-normally distributed data was
analyzed by Mann-Whitney test. Normally distributed data was analyzed by unpaired
student’s t-test, with Welch’s correction applied if the two groups differed in variance by
F test. ELISA data and intracellular cytokine staining were analyzed by two-way
ANOVA, followed by Tukey’s multiple comparison test if initial ANOVA was
significant. Human cord blood data was non-normally distributed by Shapiro-Wilk test
and analyzed for differences by Mann-Whitney test. Cord blood data was also divided by
fetal sex and analyzed by two-way ANOVA to determine if fetal sex was a significant
factor contributing to variance.
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Supplemental Figures

Figure S4.1: Flow Cytometry Gating Scheme. Cells from maternal spleen, decidua, placenta, amniotic
fluid, and fetal liver were analyzed using the following gating scheme. Gates were determined with the use
of fluorescence-minus-one controls.
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Figure S4.2: Intrauterine inflammation does not alter systemic maternal immune populations.
Maternal spleens were harvested at 48 and 72 hours post-uterine injection and immune populations were
identified by flow cytometry. 106 events from each spleen sample were run on the flow cytometer. IUI had
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no significant effect on the maternal splenic immune populations examined, including: (A) CD45+ cell
count, (B) macrophages, (C) CD4+ T cells, (D) CD8+ T cells, (E) regulatory T cells, (F) g/d T cells, (G) B
cells, (H) NK cells, (I) neutrophils, and (J) dendritic cells.

Figure S4.3: Decidual g/d T cells were increased 72 hours post-exposure to intrauterine
inflammation. Decidua, placenta, amniotic fluid, and fetal liver were harvested at 48 and 72 hours post
uterine injection and immune populations were analyzed by flow cytometry. Specifically, non-debris,
single, live, CD45+, CD19-, CD4-, CD8-, Ly6G-, F4/80-, CD49b-, CD3+, g/d TCR+ cells were counted in
each tissue: (A) decidua, (B) placenta, (C) amniotic fluid, and (D) fetal liver. All samples were analyzed by
Shapiro-Wilk test for normality and F-test for unequal variance. Significance for decidual cells was
determined by unpaired t-test with Welch’s correction for unequal variance due to positive F-test.
**:p<0.01.
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Chapter 5: Future Directions and Clinical Implications
This body of work addresses three questions facing both clinical perinatology and basic
reproductive immunology: (1) What regulates the timing of parturition? (2) How do
uterine immune cells regulate fetal survival? (3) How do inflammatory signals traffic
across the placenta? While the data presented introduce new potential mechanisms to
address key components of these questions, each new piece of information also creates
new questions. In this chapter, I will address both scientific next steps and the potential
for translational impact in relation to each core question.
Regulation of Parturition
Regulation of the timing of parturition is a very basic scientific topic. Why is the
gestational period for mice 20 days, for humans 266 days, and elephants 640 days
(Watkins, 2009)? The data presented in Chapter 2 adds an additional piece to an already
complex biologic event: that placental immune modification may impact parturition
along with the massive hormonal changes, uterine muscular contractions, and cervical
dilation that have already been reported. Our data show a decrease in placental Tregs near
term, perhaps lifting the inflammatory “breaks” to allow for labor. Multiple models of
preterm parturition have shown that inflammation at the maternal-fetal interface, whether
activated T cells, neutrophils, or cytokines (IL-1b and IL-6), can initiate labor (ArenasHernandez et al., 2019; Leitner et al., 2014; Novak et al., 2019; Tulina et al., 2018). We
find that the inflammatory milieu of preterm and term parturition are not the same,
implying that preterm labor is not simply “early” but a different pathologic process
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involving recruited pathological cells (neutrophils) rather than the absence of regulatory
cells (Tregs and dendritic cells).
Many of the logical follow-up experiments to this research have already been
completed by other groups. For example, depletion of Tregs at E14.5 using the FoxP3DTR model results in 15% preterm parturition (Gomez-Lopez et al., 2020). Additionally,
adoptive transfer of Tregs can rescue models of CpG-mediated preterm parturition (Y.
Lin et al., 2014) and LPS-induced preterm parturition (Gomez-Lopez et al., 2020).
Interestingly, depletion of neutrophils did not prevent preterm parturition caused by
intrauterine injection of 107 heat-killed E. coli (Filipovich et al., 2015). Neutrophils may
be part of the inflammatory cascade leading to preterm parturition without being
necessary to cause parturition.
For greater translational impact, the next steps should test potential preterm parturition
prediction and prevention strategies. Currently, prior preterm birth and short cervical
length are the clinically used predictors of preterm parturition. However, these predictors
have a low sensitivity for predicting preterm parturition, although the exact sensitivity
has greatly varied between studies (from 6 to 76% sensitivity) (Berghella, 2020; Suff et
al., 2018). Our laboratory was involved in a clinical study of the microbiome of 2000
pregnant women that analyzed both microbes and antimicrobial peptides in the
cervicovaginal space over gestation in a prospective cohort to identify stronger predictors
of preterm parturition (Elovitz et al., 2019). This study identified specific bacterial taxa
with elevated hazards ratios for preterm parturition, which could be used to predict the
likelihood of preterm birth in patients. Our lab has been developing mouse models of
preterm parturition that more closely mimic the human condition, specifically by
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colonizing the mouse cervical vaginal space with microbes associated with preterm
parturition that were identified in this study (Elovitz et al., 2019). If we can recapitulate
preterm parturition initiated by a cervicovaginal microbe, we can test both immune and
microbial interventions to remediate the preterm phenotype.
Current clinical strategies for preventing preterm parturition have low efficacy.
Intravaginal progesterone is the primary clinical prevention strategy, but progesterone
only decreases the relative risk of preterm parturition by 0-30% when compared to
placebo, depending on the study (Meis et al., 2003; Norman et al., 2016). Cervical
cerclage has also been used to prevent preterm parturition, and it does reduce the relative
risk of preterm parturition but does not reduce the relative risk of neonatal morbidity
(Alfirevic et al., 2017), perhaps because cerclage is an anatomical strategy to prevent
preterm parturition, which does not address the fetal damage of the underlying etiology:
inflammation. An IL-1 receptor antagonist, rytvela, is in preclinical studies to prevent
preterm parturition, based on animal models that have found IL-1b critical to the
pathogenesis of preterm parturition (Nadeau-Vallée et al., 2015). New strategies based on
the pathogenesis discovered in animal models should be pursued.
An important aspect of the study presented in Chapter 2 is examining the placenta over
time at multiple gestational time points. It has been assumed that the placental immune
populations change over time, but most studies have used single time points to describe
the placental immune status of the placenta. New computational work and multi-omic
approaches have shown that the maternal peripheral blood also significantly changes over
gestation. This gestational time course data is being used to create a computer algorithm
that may be able to predict the timing of parturition based on maternal peripheral immune
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parameters (Aghaeepour et al., 2017; Stelzer et al., 2021; Tarca et al., 2021). Such novel
and multidisciplinary approaches may someday clarify these remaining questions on
parturition and more accurately identify patients at risk of preterm parturition.
Immune Mechanisms of Late Fetal Loss
The data presented in Chapter 3 identifies a novel uterine macrophage population that
may be beneficial in preventing late fetal loss. The Trem2+ C1q+ MHC-IIlow uterine
macrophage (TCM) has a gene signature that suggests specific roles and functions for
TCMs in pregnancy, but these functions have not yet been evaluated. TCMs require
rigorous evaluation to fully understand how this cell type modulates the uterine
environment to promote fetal health. Prior literature on uterine macrophages in midgestation support a role for uterine macrophages in clearing apoptotic trophoblasts to
prevent immune activation against identified danger-associated molecular patterns
(DAMPs) and fetal antigens (Abrahams et al., 2004). This role is supported by genes
enriched in TCMs: the high expression of lysosomal and C1q genes (Figure 3.8B)
suggests active phagocytosis (Galvan et al., 2012). The increase of TCMs induced by
Tregs is also consistent with a role in phagocytosing apoptotic debris, as Tregs can
induce efferocytosis in macrophages (Proto et al., 2018). In addition, one role of tumorassociated macrophages, which share a genetic signature with TCMs, is engulfing dead
tumor cells to prevent T cell anti-tumor responses and promote an anti-inflammatory
environment (Cunha et al., 2018). Therefore, investigation of the potential phagocytic
roles of TCMs is a key next step.
In order to test the phagocytic capability of TCMs, macrophages would be sorted from
the uterus of C3H/HeN (C3H) mice with healthy pregnancies. Specifically, Trem2+
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MHC-IIlow, Trem2- MHC-IIlow, and MHC-II+ macrophages would be sorted from the
uteri of mid-late gestation C3H pregnant dams for use in multiple in vitro assays.
Phagocytic ability of each uterine macrophage type could be measured by FITC-labeled
latex beads for general phagocytosis or of Live/Dead stained heat-killed splenocytes for
phagocytosis of dead cells. This experiment would not only differentiate the phagocytic
ability of each uterine macrophage, but also determine if Trem2 is a specific marker for a
phagocytic macrophage subtype.
To examine whether there are excess apoptotic cells in the uterus of untreated CBA
mice, we would save paraffin imbedded sections of implantation sites from E12 untreated
CBA mice, Treg-recipient CBA mice, and untreated C3H mice. We would complete
immunohistochemistry (IHC) staining of F4/80 for macrophages, cytokeratin 7 (CK7) for
trophoblasts, CD31 for endothelial cells, and terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining for apoptotic cells to quantify macrophages,
trophoblasts, endothelial cells, and apoptotic cells. These histopathology results would
also allow us to measure the depth of trophoblast invasion and the anatomy of uterine
arteries (arterial wall thickness and lumen diameter) and whether these parameters are
altered in CBA mice with or without Treg treatment, illuminating whether Treg treatment
alleviates a placentation defect in CBA mice.
The use of knockout mice would define the roles of specific genes and their impact on
late fetal loss. C1q knockout mice have already been shown to have abnormal pregnancy
outcomes with increased fetal resorption, lower fetal weight, and an absence of
perivascular trophoblasts (Agostinis et al., 2010). Interestingly, C1q-knockout females
mated to wildtype males had normal pregnancies, while wildtype females mated to C1q118

knockout males have a pre-eclampsia like syndrome with albuminuria, elevated mean
arterial pressures, and increased fetal resorption (Singh et al., 2011). In contrast to our
CBA findings, which are dependent on maternal genotype (Figure 3.2), this phenotype
seems dependent on paternal genotype.
No adverse reproductive phenotype has been reported in Trem2 knockout mice. We
bred Trem2 knockout female mice to wildtype C57BL/6 male and bred wildtype
C57BL/6 mice in our colony and found only a very small difference in the number of
viable fetuses. Additional studies could be done to further examine this minor phenotype.
For example, Trem2 knockout females could be bred to BALB/c males or another
allogeneic male mouse to see if fetal antigen plays some role in the Trem2 macrophage
interaction.
A.

B.

C.

Figure 5.1: Pregnancies in Trem2-deficient female mice have slightly fewer fetuses than those in
wildtype mice. Trem2 knockout (Trem2 KO) and C57BL/6 wildtype (WT) females were both bred
C57BL/6 wildtype males. At E13-E15, pregnant mice were sacrificed and (A) viable-appearing fetuses
were counted and the fetal loss was reported by both (B) the rate in each dam and (C) total counts of
implantation sites. Mann-Whitney test was used to compare (A) viable fetuses and (B) the rate of fetal loss
due to positive Shapiro-Wilk tests showing non-normally distributed data. Fisher’s exact test was used to
compare (C) implantation site counts. The specific p-values are listed on each graph.
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While most commercially available knockout mice are on a C57BL/6 background, we
find that C57BL/6 wildtype mice have an adverse reproductive phenotype at baseline.
For example, C57BL/6 mice have reduced fertility, as indicated by their rate of
copulation plugs without subsequent pregnancy (also known as a false plug rate) of
36.4%, while the false plug rate for CBA mice is 11.9% and for C3H/HeN mice is 9.7%
in our colony (Figure 5.2). The development of a Trem2 knockout mouse on a C3H
background using the CRISPR-Cas9 system would be potentially more insightful, as C3H
mice have healthier pregnancies at baseline that C57BL/6 mice. This would also allow
for interesting adoptive transfer experiments between C3H mice and CBA mice, because
both are MHC-II haplotype H-2k. For example, C3H bone marrow derived macrophages
could be transferred into CBA mice from wildtype C3H and Trem2 knockout C3H mice
to see if (1) macrophages could rescue the CBA phenotype and (2) if so, whether Trem2
was necessary for the rescue.
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Figure 5.2: C57BL/6 mice have reduced fertility. Female mice were placed in the same cage as a male
mouse of an allogeneic strain (BALB/c or DBA/2). All cages were checked for copulation plugs 12-16
hours later, and plugged females were removed from male cages and kept in female-only cages for two
weeks. At two weeks it was determined if the plugged females were pregnant. Difference analyzed by Chisquare test with p-value = 0.0001.

Additionally, the single-cell RNA-sequencing data created with this model of fetal loss
could be the starting point for multiple other lines of experimental inquiry. Treg adoptive
transfer decreased the number of neutrophils found in the CBA uterus, and so the role of
neutrophils in pregnancy loss could also be examined. We did not initially follow up on
this finding because there were equivalent numbers of neutrophils in the uteri of CBA
and C3H mice, while C3H uteri had higher numbers of Trem2+ MHC-IIlow macrophages.
Neutrophils are elevated in the uterus during other adverse perinatal outcomes, such as
preterm parturition (Figure 2.5D) so may also play a role in IUFD.
The CBA mouse model could also be used for initial animal trials of therapeutics that
would prevent IUFD. For example, a modified recombinant C1q has been created that
can activate phagocytosis but not activate the rest of the complement cascade
(Espericueta et al., 2020). These recombinant C1q variants have been used to enhance
macrophage clearance of oxidated low-density lipoprotein (LDL) without causing the
subsequent pro-inflammatory response of the complement cascade (Espericueta et al.,
2020). If the CBA mouse does have a defect in uterine macrophage efferocytosis, treating
with these recombinant C1q variants may increase macrophage efferocytosis without
increasing inflammation, and potentially ameliorate the CBA reproductive phenotype.
A therapeutic for IUFD would require clinicians to identify pregnancies at risk for
IUFD. CBA mice had fewer splenic Tregs than C3H mice during pregnancy (Figure
3.3E), so there may be a maternal systemic biomarker that could indicate an at-risk
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pregnancy. Current clinical factors that are known to contribute to an increased likelihood
of IUFD include a prior IUFD, abnormal uterine artery flow, and fetal growth restriction.
A prior IUFD increases the likelihood of future IUFD by 10-fold (Reddy, 2007).
Abnormal uterine artery Doppler studies after 20 weeks gestation are associated with
increased rates of preeclampsia, fetal growth restriction, and IUFD – with specific
Doppler findings correlating to specific risks (Reddy, 2007). Fetal growth restriction is
present in nearly half of fetal demises, and profound small for gestational age (below two
standard deviations below the mean) has an elevated risk of fetal death (Reddy, 2007).
These varying factors could be used, potentially in combination with maternal blood
values such as Treg counts, to predict whether a prophylactic treatment for IUFD should
be initiated.
Overall, this study provided a novel mechanism of IUFD with a focus on interactions at
the maternal-fetal interface. Single-cell RNA sequencing provides a tremendous tool in
understanding the complexity of a tissue. To determine mechanisms of other diseases in
pregnancy – from miscarriage to preeclampsia – highly detailed tools and new
technologies will need to be used, just as they have been in other disease states.
Intrauterine Inflammation Induced Fetal Neuronal Injury
The data presented in Chapter 4 demonstrates a plausible mechanism by which
intrauterine inflammation could cause fetal brain damage with long-lasting
neurobehavioral consequences. However, we do not show that g/d T cells are necessary
for brain injury. The next step would be to recreate this model in C57BL/6 mice so that
we could utilize the commercially available TCRd knockout mouse strain. We have
previously shown that C57BL/6 mice have a roughly 10-fold lower tolerance for
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intrauterine LPS than CD-1 mice. In our mouse colony, a 10µg intrauterine injection of
LPS leads to a 70% preterm birth rate in C57BL/6 mice, while the dose we use in our
fetal brain injury model in CD-1 mice is 50µg, leading to a 30-50% preterm birth rate.
Once we establish an LPS dose for pregnant C57BL/6 mice (perhaps 5µg) in which some
mice give birth preterm but the majority carry to term, we will evaluate for brain damage
in fetal, neonatal, and adult offspring exposed to intrauterine inflammation, replicating
our existing data in CD-1 mice (Burd et al., 2009, 2010, 2011; Elovitz et al., 2011; Hester
et al., 2018; Makinson et al., 2017). The following next steps assumes that this can be
successfully achieved.
One critical line of inquiry is whether the g/d T cells in the fetal brains of intrauterine
inflammation (IUI)-exposed fetuses are fetal or maternal in origin. Given that this model
exposes mice at E15, the earliest g/d T cells will already be developed in the fetus (Ribot
et al., 2021). These early g/d T cells, are known to mostly express IFNg (Ribot et al.,
2021), which is consistent with our findings in the brain. Therefore, I hypothesize that the
g/d T cells in the fetal brain are fetal in origin. To test this hypothesis, I would set up the
following mating scheme (shown in Figure 5.3): heterozygous female mice TCRd +/with homozygous male TCRd -/-. With this mating, all mothers will have g/d T cells, but
only half of the fetuses will have g/d T cells. Following our usual model, pregnant dams
would be exposed to IUI (or PBS control) and then surviving pups would be genotyped
for TCRd. Previous work in our lab has shown reduced neurogenesis in postnatal day 7
mice exposed to IUI (Hester et al., 2018). We would compare control mice to IUIexposed mice with and without g/d T cells, to determine if the fetal presence of g/d T cells
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is required for the outcome of neuronal injury. If only the pups with TCRd have brain
injury, the fetal g/d T cells are necessary for brain injury. If all the pups have brain injury,
then either the injurious g/d T cells are maternal or g/d T cells are not necessary for fetal
brain injury. In the case of the latter result, we would mate a homozygous
TCRd knockout female with a heterozygote male induce IUI. If brain injury is still
present, then another cell type is responsible for the pathology.
If g/d T cells are required for neuronal injury, the next question would be whether
IFNg is necessary to the pathogenicity of g/d T cells. A conditional knockout of IFNg,
solely in g/d T cells (TCRd-Cre IFNg-floxed) would demonstrate whether specifically g/d
T cell production of IFNg is necessary for fetal brain injury.
This model also brings up questions of maternal cells trafficking into fetal spaces. The
neutrophil increases seen in the decidua, placenta, amniotic fluid, and fetal liver (Figures
4.1B-C, 4.2E-F, 4.4G) could all be maternal or maternal neutrophils may only be present
in the decidua and placenta. Using this model on a C57BL/6 background would also let
us easily identify maternal from fetal immune cells by mating CD45.1 and CD45.2
congenic mice. In this mating, all fetal immune cells would be double positive for
CD45.1 and CD45.2 versus the maternal immune cells would only be positive for one.
Whether maternal neutrophils and other immune cells have the ability to cross the
placenta in certain scenarios and seed the fetal liver would have tremendous implications
for the immune education, immune activation, and pathogen exposure of the fetus.
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Figure 5.3: Experimental schematic to determine whether maternal or fetal g/d T cells are
necessary for fetal brain injury. Genotypes are indicated by the color of the mouse: green indicates a
TCRd heterozygote (+/-) and red indicates a homozygote TCRd knockout mouse.

Early detection of fetal neuronal injury is critical to preventing the adverse long-term
consequences and neurobehavioral disorders. As noted in Chapter 4, we find IFNg in the
cord blood of term neonates with histological chorioamnionitis – a known risk factor for
brain injury. As we learn more about the in utero pathogenesis of fetal brain injury, more
biomarkers may be identified in cord blood or neonatal blood that would lead to early
diagnosis and treatment. Unfortunately, we have not identified maternal systemic signals
of intrauterine inflammation because the inflammation remains local (Figure S4.2), and
as such prenatal diagnosis and treatment is not yet feasible.
Concluding Remarks
The data in this body of work demonstrate the importance of tissue-specific immunity.
In each anatomic space, from the draining lymph nodes to each layer of the maternal-fetal
interface to the fetal brain, there are different cells present, different cells responding to
stimuli, and different responses to those stimuli. Much of immunology is context
dependent, and that context is created by the surrounding environment – the stromal cells,
cytokines, hormones, microbes, and metabolites present in that tissue. Donna Farber
recently wrote a comment article entitled “Tissues, not blood, are where immune cells
function,” in which she describes how tissue-specific immunology has paved the way for
more therapeutics and clinical change (Farber, 2021). The importance of tissues and the
entire tissue micro-environment must be examined when investigating an immune
phenotype. This has been demonstrated repeatedly in each section of the gastrointestinal
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tract, in tumor-microenvironments, and in levels of the airway. The same holistic view
must be applied to the immune functions of the female reproductive tract.
Dr. Farber also advocates for greater access to human tissues for research scientists.
Our access to reproductive tissues is extremely limited, hence the need for so many
animal models. Most of the tissues that we have access to are postpartum – after a
massive physiologic event has occurred within the tissue – and not likely representative
of the status of the tissue prior to parturition. Elective abortions are one of the very few
sources of ‘normal’ human reproductive tissues that haven’t undergone miscarriage or
parturition. In June 2019, the Trump administration banned the use of NIH funds for any
work relying on fetal tissues or cells. This ban was reversed in April 2021, demonstrating
that fundamental tools to our work as reproductive immunologists and biologists can be
eliminated or reinstated simply by politician’s signature.
Birth is the truly universal experience, with life-long consequences. Prenatal epigenetic
programming greatly affects immunologic, neuropsychiatric, and metabolic
characteristics throughout one’s lifetime. The uterine environment, including nutrient
availability, oxygenation, and inflammation, all impact prenatal programming. Yet far
less is known about the tissue immunology of the uterus than the duodenum or the
nasopharynx. Pregnancy, despite or because of its literal essentiality, is seen as “natural”
– not in the way a cardiac rhythm is natural, but in a way that does not require further
investigation (Ortner, 1972). We normalize the suffering of pregnant patients by calling
maternal pain and morbidity “natural,” as though birth trauma were not possible to
prevent or research or understand. As such, to scientifically investigate pregnancy is not
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only to intellectually explore new data, nor only to uncover new therapeutics, but also to
elevate the dignity of pregnancy and pregnant patients as worthy of modern science.
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